

# Vaccines and Global Health: The Week in Review 05 July 2025 :: Issue 806 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

## Milestones, Perspectives

#### Editor's Note:

We lead this edition with an OECD analysis which models further cuts to ODA/foreign assistance and the high-level impacts on UN system agencies, multilateral institutions and their development and global health programs over the near-term. This is followed by a study from *The Lancet* evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030.

These analyses underscore the importance of global development and health financing, addressed to some degree by the just-concluded Fourth International Conference on Financing for Development and its *Sevilla Commitment and Platform for Action* which "...lays out a path to close the \$4 trillion annual SDG financing gap in developing countries...the first inter-governmentally agreed financing for development framework since 2015."

::::::::

## **ODA/Foreign Assistance**

<u>Cuts in official development assistance – OECD projections for 2025 and the near term</u>

OECD Policy brief

26 June 2025

PDF: <a href="https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/06/cuts-in-official-development-assistance">https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/06/cuts-in-official-development-assistance</a> e161f0c5/8c530629-en.pdf

## 'Key messages


- The OECD projects a 9 to 17% drop in official development assistance (ODA) in 2025. This comes on top of a 9% drop in 2024. The outlook beyond 2025 remains highly uncertain.
- The projected decline is driven by announced cuts in four major providers of ODA. For the first time in nearly 30 years, France, Germany, the United Kingdom, and the United States all cut their ODA in 2024. If they proceed with announced cuts in 2025, it will be the first time in history that all four have cut ODA simultaneously for two consecutive years.
- ODA in 2027 is projected to fall back to 2020 levels. That said, needs continue to grow and the projected ODA cuts will impact the poorest countries and vital services hardest.
  - o In 2025, least developed countries (LDCs) are projected to see a 13-25% fall in net bilateral ODA from DAC providers. Countries in sub-Saharan Africa could face a 16-28% decline.
  - Bilateral ODA for health is projected to decline by 19-33 % in 2025 over 2023 levels, marking further falls from previous high levels related to COVID-19 support. ODA for health in 2025 is projected to fall below pre-COVID-19 levels.
  - Anticipated cuts to multilateral organisations may trigger a second wave of funding decreases for the poorest countries and vital services. In 2023, nearly half of ODA to LDCs was delivered through multilateral channels. The eleven providers that have announced cuts account for between 62% (for WHO) and 87% (for WFP) of funding to key multilateral health and humanitarian agencies.
- Co-ordinated action is critical to avoid major impacts on the countries and people most in need. Providers could:
  - Share forward plans, information, and analysis on the implications of evolving ODA levels and allocations, underpinned by data and evidence;
  - Work together, and with countries and territories that receive ODA, to find solutions to close finance gaps, and protect and sustain focus on the highest impact programmes and investments, especially for countries, sectors, and populations most in need;
- Diversify partners, pool resources, catalyse private sector investment where appropriate, and support the mobilisation of domestic resources.

## [Excerpt]

## **Box 2. Outlook for United States' foreign assistance**

In 2025, the United States announced significant cuts to its foreign assistance (Pamuk, 2025[8]). The FY2026 Department of State budget request includes:

- A two-thirds reduction in funding for bilateral global health programmes, including a 50% cut for HIV/AIDS and no allocations to the Global Fund, Gavi, the Vaccine Alliance, or the World Health Organisation.
- No funding for the African Development Bank's concessional window, amounting to a USD 155 million cut over 2026–2028 for the ADF-17 replenishment.
- A 75% cut in funding for the Millennium Challenge Corporation (for 51 developing countries across a range of income groups).
- Funding for three new accounts: USD 1.5 billion for the President's Emergency Refugee and Migration Assistance; USD 2.9 billion for the America First Opportunities Fund1; and USD 2.5 billion for a consolidated international humanitarian assistance account that merges two entities (one account and one fund) and represents a 66% cut from FY2025 levels (U.S. Department of State, 2026[9])...



Notes: 1 With the exception of GAVI, figures are based on two-year averages of core and non-core gross disbursements. 2 GAVI figures include 2021-25 direct contributions and pledges, including to the International Finance Facility for Immunisation, but exclude contributions to COVAX. 3 WHO figures include both core voluntary and assessed contributions but exclude contributions to the WHO Strategic Preparedness and Response Plan.

Sources: OECD (2025[24]), OECD Data Explorer, Providers' total use of the multilateral system, <a href="http://data-explorer.oecd.org/s/1td">http://data-explorer.oecd.org/s/1td</a>; GAVI (2025[25]), Funding, <a href="https://www.gavi.org/investing-gavi/funding">https://www.gavi.org/investing-gavi/funding</a>.

...The FY2026 budget request also proposes rescinding USD 9.6 billion of previously approved budget authority for State and International Affairs (U.S. Department of State, 2025[10]). On 12 June, the House approved rescinding USD 8.3 billion of foreign assistance from earlier appropriations (U.S. House of Representatives, 2025[11]). The Senate must approve this package by mid-July for it to take effect (Collinson and Hurley, 2025[12]). If passed, these cuts – mainly affecting global health and disaster relief – would reduce disbursements starting in 2026 and exacerbate planned cuts to these sectors...

Sources: Collinson and Hurley (2025[12]); U.S. Department of State (2025[10]); Office of Management and Budget (2025[15]); Pamuk (2025[8]); Professional Services Council (2025[14]); U.S. House of Representatives (2025[11]); Center for Global Development (2025[13]).

::::::::

<u>UNAIDS</u> welcomes the outcome of the 4th International Conference on Financing for Development and the ambition of the Seville Platform for Action for global health, debt restructuring and fair taxation

Press Release

GENEVA/SEVILLE, 2 July 2025—At the 4th International Conference on Financing for Development, UNAIDS has welcomed the Financing for Development outcome document adopted by 192 countries in a time of multilateral distress. The new Seville Platform For Action calls for actionable and coordinated global efforts to transform and strengthen global health architecture, to advance debt restructuring, strengthen tax authorities and enable more progressive taxation of the wealthy and corporations...

:::::::





4th International Conference on Financing for Development 30 June - 3 July 2025

<u>Press release | Fourth International Conference on Financing for Development delivers renewed hope and action for sustainable development</u>

The Sevilla Commitment and Platform for Action advance concrete strategic steps to fulfill the promise of the Sustainable Development Goals and chart a path for a fairer shared future, reaffirming the role of global cooperation

Sevilla, Spain, 3 July 2025 – The Fourth International Conference on Financing for Development concluded today in Sevilla, Spain, with 130 initiatives turning the <u>Sevilla Commitment or Compromiso de Sevilla</u> into action through concrete steps to boost investment in sustainable development, address the debt crisis afflicting many of the world's poorest countries, and give developing countries a stronger voice in the international financing architecture.

"The human consequences of rising debt burdens, escalating trade tensions and steep cuts to official development assistance have been brought into sharp relief this week," the United Nations Deputy Secretary-General Amina Mohammed said in closing remarks. "Yet, against this sobering backdrop, the Sevilla conference delivered a strong response—a unifying outcome document focused on solutions that reaffirms the Addis Ababa commitments made a decade ago, renews hope through the SDGs, and shows that multilateral cooperation still matters and still works...

The Sevilla Commitment, adopted by consensus at the start of the Conference, lays out a path to close the \$4 trillion annual SDG financing gap in developing countries. It is the first inter-governmentally agreed financing for development framework since 2015, and a rallying call to overhaul a system that is failing billions of people and pushing global goals further out of reach.

At a time of rising debt, declining investment, shrinking aid and escalating trade tensions, sustainable development faces unprecedented headwinds. The consequences are stark: 3 billion people live in countries that spend more on interest payments than on health or education.

With five years left to achieve the SDGs in increasingly uncertain times, the Sevilla Commitment charts a path on three fronts:

- 1. Catalyzing investment at scale for sustainable development
- 2. Addressing the debt and development crisis
- 3. Reforming the international financial architecture...

::::::::

#### The Lancet

Online first June 30, 2025 Open access *Articles* 

Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis

Daniella Medeiros Cavalcanti, Lucas de Oliveira Ferreira de Sales, Andrea Ferreira da Silva, Elisa Landin Basterra, Daiana Pena, Caterina Monti, Gonzalo Barreix, Natanael J Silva, Paula Vaz, Francisco Saute, Gonzalo Fanjul, Quique Bassat, Denise Naniche, James Macinko, Davide Rasella Open Access

Summary

Background

The US Agency for International Development (USAID) is the largest funding agency for humanitarian and development aid worldwide. The aim of this study is to comprehensively evaluate the effect of all USAID funding on adult and child mortality over the past two decades and forecast the future effect of its defunding.

Methods

In this retrospective impact evaluation integrated with forecasting analysis, we used panel data from 133 countries and territories— including all low-income and middle-income countries (LMICs)—with USAID support ranging from none to very high. First, we used fixed-effects multivariable Poisson models with robust SEs adjusted for demographic, socioeconomic, and health-care factors to estimate the impact of USAID funding on all-age and all-cause mortality from 2001 to 2021. Second, we evaluated its effects by age-specific, sex-specific, and cause-specific groups. Third, we did several sensitivity and triangulation analyses. Lastly, we integrated the retrospective evaluation with validated dynamic microsimulation models to estimate effects up to 2030. *Findings* 

Higher levels of USAID funding—primarily directed toward LMICs, particularly African countries—were associated with a 15% reduction in age-standardised all-cause mortality (risk ratio [RR] 0·85, 95% CI 0·78–0·93) and a 32% reduction in under-five mortality (RR 0·68, 0·57–0·80). This finding indicates that 91 839 663 (95% CI 85 690 135–98 291 626) all-age deaths, including 30 391 980 (26 023 132–35 482 636) in children younger than 5 years, were prevented by USAID funding over the 21-year study period. USAID funding was associated with a 65% reduction (RR 0·35, 0·29-0·42) in mortality from

HIV/AIDS (representing 25·5 million deaths), 51% (RR 0·49, 0·39–0·61) from malaria (8·0 million deaths), and 50% (RR 0·50, 0·40–0·62) from neglected tropical diseases (8·9 million deaths). Significant decreases were also observed in mortality from tuberculosis, nutritional deficiencies, diarrhoeal diseases, lower respiratory infections, and maternal and perinatal conditions. Forecasting models predicted that the current steep funding cuts could result in more than 14 051 750 (uncertainty interval 8 475 990–19 662 191) additional all-age deaths, including 4 537 157 (3 124 796–5 910 791) in children younger than age 5 years, by 2030.

## Interpretation

USAID funding has significantly contributed to the reduction in adult and child mortality across lowincome and middle-income countries over the past two decades. Our estimates show that, unless the abrupt funding cuts announced and implemented in the first half of 2025 are reversed, a staggering number of avoidable deaths could occur by 2030.

Funding

The Spanish Ministry of Science and Innovation, UK Medical Research Council, and EU Horizon Europe.

[Excerpts]

#### ...Research in context

## Evidence before this study

Despite the US Agency for International Development (USAID) being the world's leading donor for humanitarian and development aid, there is scarce evidence in the literature assessing its impact on global health. Few evaluations have attempted to estimate the effects of USAID funding on maternal and child mortality in selected low-income and middle-income countries (LMICs), and some reports have offered only approximate estimates for specific diseases. Since the onset of substantial funding cuts, few studies have evaluated the consequences of reductions in USAID-funded interventions. In a few cases, websites have provided rough estimates on the cumulative effect of these cuts on tuberculosis, child mortality, and other health diseases or conditions.

## Added value of this study

To our knowledge, this study is the first comprehensive analysis to assess the impact of total USAID funding—including support for health care, nutrition, humanitarian aid, development, education, and related sectors—on mortality in LMICs over the past two decades. Our study also disaggregates effects by age group and cause of death. Importantly, it is the only study to integrate retrospective evaluations with forecasting models that project the effects of current and proposed funding cuts on child and all-age mortality to 2030. We estimate that over the past two decades, USAID-funded programmes have helped prevent more than 91 million deaths globally, including 30 million deaths among children. Projections suggest that ongoing deep funding cuts—combined with the potential dismantling of the agency—could result in more than 14 million additional deaths by 2030, including 4·5 million deaths among children younger than 5 years. These results provide essential evidence for policy makers, planners, and advocates navigating the future of US global health engagement.

## Implications of all the available evidence

USAID funding has had a crucial role in improving global health, particularly by reducing mortality from poverty-related diseases and saving the lives of millions of adults and children. **Current and proposed US aid cuts—along with the probable ripple effects on other international donors—threaten to abruptly halt and reverse one of the most important periods of progress in human development**. For many LMICs, the resulting shock would be similar in scale to a global pandemic or a major armed conflict. Unlike those events, however, this crisis would stem from a conscious and avoidable policy choice—one whose burden would fall disproportionately on children and younger populations, and whose consequences could reverberate for decades...

	Number of deaths at all ages	Number of deaths in children younger than 5 years
2025	1 776 539 (967 604–2 496 308)	689 900 (436 368–911 004)
2026	2 499 525 (1 521 410-3 490 070)	828 970 (575 089–1 078 316)
2027	2 477 031 (1 507 936–3 458 985)	798 188 (553 276–1 039 475)
2028	2 454 816 (1 494 286-3 428 201)	768 294 (531 228–1 003 073)
2029	2 432 809 (1 480 850-3 396 272)	739 719 (513 316–962 867)
2030	2 411 030 (1 467 499–3 366 678)	712 098 (494 694–926 596)
2025-30	14 051 750 (8 475 990–19 662 191)	4 537 157 (3 124 796–5 910 791)

**Table 3** Mortality rate ratios and numbers of avoidable deaths from the comparison of the forecast scenario of **USAID** defunding versus baseline from **2025** to **2030**. Data are number of deaths (95% uncertainty intervals). USAID=US Agency for International Development.

#### Discussion

...Following the announcement of the termination of more than 83% of USAID's programmes, humanitarian organisations have raised serious concerns about the absence of adequate notice or planning for a phased transition. Without time to implement adaptive responses, the most severe effects cannot be mitigated. The short-term, medium-term, and long-term consequences for public health, economic development, and societal stability could be profound.

However, the US administration's decisions compound cuts by other donors, pushing both humanitarian and development systems to the brink of collapse. As a matter of fact, other western donors have announced reductions in aid budgets, <sup>41</sup> including the UK (40%), France (37%), the Netherlands (30%), and Belgium (25%), which represents a substantial funding crisis in the humanitarian and development aid sector. For 2025, the Organisation for Economic Co-operation and Development estimates official development assistance could drop between 9% and 17%. <sup>42</sup> These decreases not only threatens to reverse three decades of unprecedented human progress, but also intensifies the extraordinary uncertainty and vulnerability already caused by the ongoing polycrisis. <sup>43</sup> Although local governments have had a crucial role in the improvements observed over the past decade—often supported by development aid—they will now need to further strengthen their capacities to respond effectively in this new context.

In our study, the substantial reduction in under-five mortality observed in countries receiving the highest levels of USAID funding suggests that an important portion of the global decline in child deaths over the past two decades—primarily in LMICs—could be attributable to humanitarian and development aid. Between 2000 and 2023, the number of global under-five deaths decreased from 10·1 million to 4·8 million. Our projections indicate that disruptions to such aid could jeopardise this progress, making it increasingly difficult—if not impossible—for the poorest and most vulnerable countries to achieve Sustainable Development Goal target 3.2, reducing the under-five mortality rate to 25 or fewer deaths per 1000 live births by 2030.

**This study has several limitations.** First, the causal interpretation of the statistical associations must be approached with caution... An additional limitation is that the study cannot disentangle the specific interventions or causal mechanisms through which USAID per capita funding produces its effects... Another limitation is that the forecasted scenarios carry inherent uncertainties, driven by two main factors: the difficulty in accurately predicting which specific USAID programmes will be reduced or terminated in the short, medium, and long term; and the inability to account for exogenous shocks, given the current volatility of the global economic and political landscape.. Another limitation is that the forecasted scenarios carry inherent uncertainties, driven by two main factors: the difficulty in accurately predicting which specific USAID programmes will be reduced or terminated in the short, medium, and long term; and the inability to account for exogenous shocks, given the current volatility of the global economic and political landscape.

Despite these limitations, the main strength of our study lies in the extensive range of sensitivity analyses done, all of which consistently confirmed the robustness of our findings. Additionally, triangulation analyses using difference-in-differences combined with propensity score matching models provided further validation, strengthening confidence in the causal interpretation of the ex-post impact evaluation associations. Furthermore, the integration of these findings with validated microsimulation models enhanced the reliability of the forecasted scenarios (appendix pp 39–44).

In conclusion, our study demonstrates the crucial role that USAID funding has had in reducing mortality rates across LMICs over the past two decades, and the profound effect that the recent abrupt funding cuts could have on adult and child mortality in the coming years. **Beyond causing millions** of avoidable deaths—particularly among the most vulnerable—these cuts risk reversing decades of progress in health and socioeconomic development in LMICs, and could substantially undermine the achievement of the 2030 Sustainable Development Goals.

......

U.S. Immunization and Public Health Governance/Policy/Funding

:::::::

#### **ACIP**

## The U.S. government is failing on vaccine policy. The Vaccine Integrity Project is here to help

It can't replace governmental advisory bodies, but it can equip clinicians with information By Michael T. Osterholm, PhD, MPH FIRST OPINION STAT, July 3, 2025

#### [Editor's text bolding]

Recently, the Department of Health and Human Services floated new standards for vaccine approvals, rescinded longstanding Covid-19 vaccine recommendations for healthy children and pregnant women, and fired all 17 members of the Centers for Disease Control and Prevention's vaccine advisory committee. These actions represent a significant shift in the federal government's approach to vaccine policy and the safeguarding of the public health.

The Vaccine Integrity Project, launched in April by the University of Minnesota's Center for Infectious Disease Research and Policy, anticipated this trajectory and the risks posed to the

widely shared goal of protecting people from vaccine-preventable diseases. Its mission is simple and urgent: to ensure that vaccine use in the United States remains grounded in the best available evidence and focused squarely on protecting the public.

Over the past several months, the project has engaged more than 80 stakeholders, including clinicians, academics, public health officials, insurers, and industry leaders, to **assess how nongovernmental actors can defend vaccine science and use at a time when official public health channels are under stress.** 

What emerged was a **shared recognition of two immediate priorities: continuing the development and dissemination of trusted evidence-based immunization guidance and countering the spread of inaccurate health information.** The Vaccine Integrity Project will soon publish its findings from these stakeholder engagements in a final report, concluding the work of its steering committee and signaling an end to its exploratory phase, shifting its focus to action.

To that end, later this summer, the Vaccine Integrity Project is convening experts from across the vaccination ecosystem to assess the evidence on influenza, RSV, and Covid-19. Our partners will use this evidence base to develop immunization guidelines.

Here's how this collaborative process is going to work: **The Vaccine Integrity Project will assemble scientific briefs for these three respiratory diseases, reflecting current virology, epidemiology, vaccine effectiveness, and safety data. We will then turn it over to medical <b>professionals associations**, whose physician members are on the frontlines providing care to Americans, to draft and disseminate vaccine recommendations and guidelines. The associations will work from this single comprehensive evidence brief, and, as needed, supplement it with data specific to individual populations.

For this effort, for example, the American College of Obstetricians and Gynecologists (ACOG) will focus on pregnant women; the American Academy of Pediatrics (AAP) on the pediatric population; the Infectious Diseases Society of America (IDSA) on the immunocompromised and high-risk populations, including the elderly; and the American Academy of Family Physicians (AAFP) on healthy adults. It is work in which the organizations have years of experience. The difference is that this summer, the process will be independent of the CDC's Advisory Committee on Immunization Practices.

Participants will disclose their conflicts of interest, and the effort will be independently funded by philanthropists.

The process described above is not a shadow ACIP. Much of ACIP's work is inherently governmental, intersecting with health insurance coverage and federal payment systems. What we are convening is designed solely to give clinicians the evidence-backed guidance they need to help protect Americans this year from respiratory viruses that hospitalize and kill tens of thousands annually. The long-term goal for everyone who cares about public health is to restore ACIP's role in the vaccine ecosystem as soon as possible.

**These actions are necessary given the measurable public health impact of vaccination efforts.** According to CDC estimates, flu vaccination alone prevented nearly 10 million illnesses, 120,000 hospitalizations, and 7,900 deaths during the 2023–24 season. And yet, more than 200 children died from the flu that same season, over 80% of whom were unvaccinated. Meanwhile, Covid-19 vaccination last year provided 50% added protection against associated hospitalizations among healthy adults over 65.

The Vaccine Integrity Project's work is inherently collaborative and is not trying to standin for government bodies. We aim to lock arms with doctors, scientists, and public health experts and promote integrity, openness, and scientific rigor.

No one group can take on all the challenges that lie ahead, including building infrastructure to support state and local health departments, stabilizing vaccine safety systems, protecting insurance coverage, and coordinating policy efforts across the ecosystem.

Now, the scientific and medical communities are stepping up to safeguard the systems they helped build over decades. In moments like this, it's important to affirm the role of science and evidence in guiding public health decisions.

Michael T. Osterholm, Ph.D., M.P.H., is McKnight Presidential Endowed Chair in Public Health and the director of the Center for Infectious Disease Research and Policy at the University of Minnesota. He is also a member of the Vaccine Integrity Project Steering Committee.

::::::::

## **U.S. Defunding of Gavi**

## The Trump Administration's Foreign Aid Review: Status of U.S. Support for Gavi, the Vaccine Alliance

Kaiser Family Foundation, Published: Jun 30, 2025 [Excerpt]

## ... Current Status of U.S. Support for Gavi:

- **Funding**: In FY 2024, U.S. funding for Gavi was \$300 million. The <u>FY 2025 Continuing Resolution</u> that passed in March included level funding of \$300 million, which marks (and would fulfill) the first year of Gavi's new pledge period. The administration's <u>FY 2026 budget request</u> does not include funding for Gavi and, while final funding levels are determined by Congress, Secretary of Health and Human Services Robert F. Kennedy Jr. has said that the U.S. will not provide additional funding to Gavi (see "Replenishment" below).
- **U.S. Representation on the Gavi Board:** The U.S. also plays a role in Gavi's governance and oversight, sharing one of the donor government board seats on Gavi's 28-member Board, and currently serving as the Board member for the seat.
- **Foreign aid review/freeze:** The foreign aid review's stop-work order initially froze all U.S. bilateral programming but was not applied to Gavi or other multilateral institutions. The administration subsequently announced that it canceled 86% of all USAID awards. KFF <u>analysis</u> finds that of 770 global health awards identified, 80% are listed as terminated, including the main Gavi contract as well as the COVAX contract. Gavi reports that it has not received a termination notice for its main contract, although it did receive one for COVAX (all U.S. funding was already disbursed to COVAX in 2021).
- **International organizations review:** A second <u>executive order</u>, calling for a 180-day review of U.S. participation in all international intergovernmental organizations, is currently underway. Per the order, the purpose of the review is to determine which are "contrary to the interests of the United States and whether such organizations, conventions, or treaties can be reformed".
- **Reorganization**: The administration <u>notified</u> Congress on March 28, 2025 of its intent to permanently dissolve USAID and that any remaining USAID operations would be absorbed by the State Department, including remaining global health activities which would be integrated into its Bureau of Global Health Security and Diplomacy (GHSD). Delivery of lifesaving vaccines is listed among the USAID activities to be continued. On May 29, 2025, the State Department further <u>notified</u> Congress of its proposed reorganization plan.

Potential impact on health outcomes: The loss of U.S. support for Gavi would affect
procurement of vaccines for LMICs, with particular impact on children. Gavi <u>estimates</u> that loss of
funding could result in 75 million children not receiving routine vaccinations over the next five
years, leading to more than 1.2 million children dying as a result. Reductions in vaccine stockpiles
could also impact outbreak control.

#### What to Watch

- Results of foreign aid and international organization reviews: The administration could soon release results of its 90-day foreign aid review (which has already been extended by 30 days), and the outcome of the review of international organizations is expected later this year. It is unknown whether there will be any recommendations related to U.S. support for or engagement with Gavi, and how or if Congress will respond to any such recommendations.
- **Reorganization:** While the administration has notified Congress that it intends to retain and integrate USAID's delivery of lifesaving vaccines activities into the State Department's GHSD, no additional information is available on what this would mean for the relationship with Gavi.
- Funding/Budget Request: The administration's FY 2026 budget request includes significant reductions in funding for global health, and does not include funding for Gavi. The administration also submitted its first rescission package to Congress, including proposed rescissions of more than \$1 billion in prior year funds for global health (little information on specific funding lines to be eliminated has been provided). Final appropriation amounts and rescission decisions are determined by Congress.
- **Replenishment:** Gavi's June 2025 pledging conference <u>raised</u> \$9 billion in funding towards its \$11.9 billion target. Last year, the Biden administration pledged <u>at least \$1.58 billion</u> over five years to Gavi's replenishment. However, Secretary Kennedy <u>announced</u> that the U.S. will not provide additional funding to Gavi unless it changes its evaluation of vaccine science and safety, among other issues. In response, Gavi has <u>stated</u> that it relies on WHO's independent, science-based, global vaccine evaluation and recommendation process. In addition, individual country requests for vaccine support from Gavi are made in line with their own national immunization policies. While final U.S. funding amounts are determined by Congress, it remains to be seen how this will unfold over the next year.

::::::::

## Polio - PHEIC

## Polio this week - 25 June 2025

**Headlines** [Selected]

**:: Mauritania and Senegal Roll Out Hexavalent Vaccine: A Major Leap for Child Health** With support from WHO, UNICEF, and Gavi, Mauritania and Senegal have introduced the hexavalent vaccine into national immunization schedules—a milestone that protects children from six deadly diseases, including polio, in a single shot. This is a transformative moment in the Region's efforts to streamline immunization and strengthen the fight against polio.

## :: Polio Assets Bolster Angola's Cholera Response

Angola is leveraging its polio infrastructure to combat a growing cholera outbreak—demonstrating how investments in eradication continue to deliver broader public health benefits. [More]

## :: Somalia Campaign Delivers Triple Protection for Children

An integrated health campaign in Somalia is reaching children with vaccines against measles, pneumonia, and polio—bringing a healthier future within reach. [More]

## Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1 case

Angola: one cVDPV2 case

- Benin: one cVDPV2-positive environmental sample

Chad: one cVDPV2 case

::::::::

## mPox - PHEIC

No new digest content identified.

::::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::::

## WHO & Regional Offices [to 05 July 2025]

https://www.who.int/news

Selected News/Announcements/Statements

3 July 2025 News release

Readout on WHO participation in global nuclear emergency exercise

2 July 2025 News release

WHO launches bold push to raise health taxes and save millions of lives

30 June 2025 News release

Suriname certified malaria-free by WHO

::::::

#### **WHO Regional Offices**

Selected Press Releases, Announcements

## **WHO African Region AFRO**

:: 03 July 2025

<u>Providing nonjudgmental and empathetic sexual and reproductive health services in</u> **Zambia** 

:: 02 July 2025

WHO actively responds to anthrax epidemic in the DRC

## **WHO Region of the Americas PAHO**

:: 3 Jul 2025

### Measles cases rise in the Americas in 2025

Washington, D.C., 3 July 2025 (PAHO) – A total of 7,132 confirmed cases of measles and 13 deaths have been reported in the Region of the Americas as of mid-June 2025, according to the latest epidemiological update from the Pan American Health Organization (PAHO). This represents a 29-fold increase compared to the 244 cases reported during the same...

#### :: 2 Jul 2025

## WHO launches bold push to raise health taxes and save millions of lives

The "3 by 35" Initiative targets tobacco, alcohol, and sugary drinks to cut deaths and boost health and development funding Geneva/Sevilla, July 2, 2025 (WHO)— The World Health Organization (WHO) today has launched a major new initiative urging countries to raise real prices on tobacco, alcohol, and sugary drinks by at least 50% by 2035...

:: 2 Jul 2025

## Noncommunicable disease deaths in the Americas have risen 43% since 2000, PAHO report shows

Washington, D.C., July 2, 2025 (PAHO)— Deaths from noncommunicable diseases (NCDs), such as heart disease, cancer, and diabetes, have surged by 43% in the Americas since 2000, reaching 6 million in 2021, according to the Pan American Health Organization's (PAHO) NCDs at a Glance 2025 report, released today. Noncommunicable diseases...

:: 30 Jun 2025

## Suriname certified malaria-free by WHO

June 30, 2025 (PAHO) | Geneva – Today, Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO). This historic milestone follows nearly 70 years of commitment by the government and people of Suriname to eliminate the disease across its vast rainforests and diverse...

#### **WHO South-East Asia Region SEARO**

No new digest content identified.

#### WHO European Region EURO

No new digest content identified.

### WHO Eastern Mediterranean Region EMRO

:: A shot at a healthier future: Somali mothers embrace lifesaving vaccines for their children

30 June 2025

#### **WHO Western Pacific Region**

No new digest content identified.

::::::

#### **WHO - Emergency situation reports**

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

**Public Health Situation Analysis - Libya** 

::::::

## **Disease Outbreak News (DONs)**

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

5 July 2025 | Avian Influenza A(H5N1) - Cambodia

:::::::

#### Weekly Epidemiological Record

Vol. 100, Nos. 27/28, pp. 265–284 4 July 2025 <a href="https://www.who.int/publications/journals/weekly-epidemiological-record">https://www.who.int/publications/journals/weekly-epidemiological-record</a> :: WHO position paper on herpes zoster vaccines – July 2025

::::::

#### **New WHO Publications**

https://www.who.int/publications Selected 4 July 2025

WHO position paper on herpes zoster vaccines

4 July 2025

WHO guidelines for clinical management of arboviral diseases: dengue, chikungunya, Zika and yellow fever

3 July 2025

## Framework to implement a life course approach in practice

Overview

The WHO Framework to implement a life course approach in practice summarizes current evidence to reorient health systems to produce health and well-being, draws on global examples of implementation, and proposes next steps. A life course approach acknowledges that health and well-being depend on the interaction of multiple protective and risk factors, particularly during sensitive and critical periods throughout people's lives and across generations. It strengthens equity by recognizing how critical periods, transitions and cumulative exposures shape health trajectories. This framework targets a wide audience including governments, civil society, and other non-state actors committed to applying a life course approach and informs discussions on redesigning primary health care programmes to improve life course health trajectories.

2 July 2025

<u>Tuberculosis and primary health care: synergies and opportunities towards universal health coverage:...</u>

30 June 2025

## Access to safe, effective and quality-assured health products and technologies Overview

The roadmap for WHO action 2025–2030 outlines to Member States, and other stakeholders WHO's unique role and approach for increasing access to safe, effective and quality-assured health products and technologies in order to reach Sustainable Development Goal targets for achieving universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all. WHO's expertise and leadership are essential for delivering the complex and wide-ranging support needed to address the many challenges in the health product and technology ecosystem. The roadmap highlights how the work of WHO aligns with and contributes to WHO's 14th General Programme of Work, particularly Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage. The roadmap outlines WHO's 5 programmatic priority areas for access to safe, effective and quality-assured health products and technologies and elaborates the priorities within each area.

30 June 2025

<u>Landscape analysis of the opportunities and challenges for neurotechnology in global</u> health

#### Overview

This report provides a detailed examination of the current landscape of neurotechnology, specifically exploring both its potential benefits and challenges from a global health perspective. The landscape analysis focuses on four emerging subcategories of neurotechnology, namely: neuroimaging, the brain computer interface (BCI), neuromodulation, and neurological devices. The report demonstrates that neurotechnology has witnessed a rapid growth in terms of both its technical development and its application across various neurological conditions. However, it also notes that despite their potential, the adoption of these emerging technologies in human health settings remains limited and challenging.

::::::

#### Editor's Note:

As a service to readers, we employ bolded red text below to identify potentially problematic content and observations added by the Editor.

## **USA – HHS, FDA, CDC+**

#### **White House**

<u>Presidential Actions – Executive Orders</u> No new digest content identified.

#### HHS

<u>News</u>

No new digest content identified.

NIH [to 05 July 2025] http://www.nih.gov/ News Releases No new digest content identified.

#### **FDA**

<u>Press Announcements</u> No new digest content identified.

CDC/ACIP [to 05 July 2025] http://www.cdc.gov/media/index.html Latest News No new digest content identified.

### **ACIP Meetings** [to 05 July 2025]

Next ACIP Meetings
:: August/September (dates TBD)
:: October 22-23

## **MMWR Weekly**

https://www.cdc.gov/mmwr/index2025.html *No new digest content identified.* 

## **FDA VRBPAC**

Advisory Committee Calendar
No new meetings scheduled.

## **FDA Pediatric Advisory Committee Meeting**

#### **Meeting Information**

July 9, 2025 Time: 10:00 a.m. - 4:00 p.m. ET

The PAC will have the opportunity to ask the Agency clarifying questions and to convey their recommendations for safety monitoring of the products listed below. The scope of the discussion will be limited to post-marketing safety and surveillance activities. No information is required from product sponsors.

- ... Center for Biologics Evaluation and Research
- a. DENGVAXIA (Dengue Tetravalent Vaccine, Live)
- b. EPICEL (cultured epidermal autografts) (HDE)
- c. FLUZONE QUADRIVALENT (Influenza Vaccine)
- d. GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)

## **National Vaccine Program**

https://www.hhs.gov/vaccines/about/index.html

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

## **Advisory Commission on Childhood Vaccines (ACCV)**

https://www.hrsa.gov/advisory-committees/vaccines/meetings

## **Next ACCV Meeting - TBD**

We are rescheduling the ACCV Meetings originally planned for Wednesday, January 29, 2025, and Thursday, January 30, 2025. Once the new dates are confirmed, information will be available here on the ACCV website and announced in the Federal Register.

.....

#### **Europe**

## **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

New ECDC weekly reports and guidance to tackle mosquito-borne diseases across Europe 1 Jul 2025

Surveillance and monitoring

## Seasonal surveillance of chikungunya virus disease in the EU/EEA

4 Jul 2025

This report gives an overview of the countries and areas where chikungunya virus disease cases – and their corresponding case numbers - have been reported to the European surveillance portal for infectious diseases (EpiPulse).

## **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news News & Press Releases No new digest content identified.

::::::

https://africacdc.org/

Press Releases, Statements [Selected]

Press Releases

## Study Validates Impact of International Teams in Africa's Outbreak Response

4 July 2025

New Africa CDC and UK-PHRST study confirms critical role international health teams have played in strengthening outbreak response across the African continent

::::::

#### China CDC+

http://www.chinacdc.cn/en/

## **National Health Commission of the People's Republic of China** [to 05 July 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

## National Medical Products Administration – PRC [to 05 July 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

**China CDC** 

## **CCDC Weekly Reports: Current Volume (7)**

2025-07-04 / No. 27

PDF of this issue

No new digest content identified.

::::::

## Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

## **Organization Announcements**

#### **Paul G. Allen Frontiers Group** [to 05 July 2025]

https://alleninstitute.org/ news-press/

Recent News

No new digest content identified.

## **BMGF - Gates Foundation** [to 05 July 2025]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements No new digest content identified.

**CARB-X** [to 05 July 2025]

https://carb-x.org/

News

No new digest content identified.

## **Chan Zuckerberg Initiative** [to 05 July 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

## **CEPI – Coalition for Epidemic Preparedness Innovations** [to 05 July 2025]

http://cepi.net/

CEPI News, Blog

No new digest content identified.

## **CIDRAP – Vaccine Inventory Project**

https://www.cidrap.umn.edu/vaccine-integrity-project

News, Viewpoints

## The U.S. government is failing on vaccine policy. The Vaccine Integrity Project is here to help

It can't replace governmental advisory bodies, but it can equip clinicians with information

By Michael T. Osterholm, PhD, MPH

FIRST OPINION, STAT, July 3, 2025

#### CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 05]

July 2025]

https://cioms.ch/

News; Publications; Events

## CIOMS cumulative glossary (version 2.3) now available

The CIOMS cumulative glossary is an organized collection of the terms and definitions included in published CIOMS Working Group reports, with a focus on pharmacovigilance.

## **CIOMS Glossary of ICH Terms & Definitions**

A glossary of ICH terms and definitions has been compiled by <u>CIOMS</u> from across ICH Guidelines. For information on this helpful CIOMS initiative, please visit the <u>CIOMS</u> website, where the glossary is freely available for download, providing a useful resource for both CIOMS and ICH Stakeholders and Working Groups.

## DARPA - Defense Advanced Research Projects Agency [U.S.] [to 05 July 2025]

https://www.darpa.mil/news

News

No new digest content identified.

## **DNDI – Drugs for Neglected Diseases initiative** [to 05 July 2025]

https://dndi.org/press/press-releases/

Press Releases

Press releases 1 Jul 2025

<u>Thailand's Government Pharmaceutical Organization (GPO) partners with DNDi and Pharco to register an effective and affordable hepatitis C treatment</u>

## **Duke Global Health Innovation Center** [to 05 July 2025]

https://dukeghic.org/

News

### **June 2025 Monthly Roundup**

June 30, 2025

The "Monthly Roundup" is a monthly newsletter dedicated to sharing the latest news from the Duke Global Health Innovation Center and Innovations in Healthcare.

## **EDCTP** [to 05 July 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

#### **Emory Vaccine Center** [to 05 July 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### **European Vaccine Initiative** [to 05 July 2025]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

## Fondation Merieux [to 05 July 2025]

http://www.fondation-merieux.org/

News, Events

Événement co-organisé par la Fondation Mérieux

<u>3ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes</u> 7-11 juillet 2025 - Cenre des Pensières, Veyrier-du-Lac (France)

#### Gates Medical Research Institute [to 05 July 2025]

https://www.gatesmri.org/news

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications No new digest content identified.

**Gavi** [to 05 July 2025] https://www.gavi.org/ Press Releases No new digest content identified.

## **GE2P2 Global Foundation** [to 05 July 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 25 May 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest May 2025

**GHIT Fund** [to 05 July 2025] https://www.ghitfund.org/newsroom/press Press Releases No new digest content identified.

**Global Fund** [to 05 July 2025]

https://www.theglobalfund.org/en/news/ News Releases 01 July 2025

#### **Global Fund Commends Suriname's Elimination of Malaria**

Suriname has officially been certified malaria-free by the World Health Organization (WHO), becoming the first country in the Amazon region to eliminate the disease. This certification marks the successful interruption of indigenous malaria transmiss...

30 June 2025

## <u>Spain and Luxembourg Make Increased Pledges Toward the Global Fund's Eighth</u> <u>Replenishment</u>

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) warmly welcomes the renewed and increased commitments from Spain and Luxembourg to end the three epidemics as public health threats, strengthen health and community systems, an...

## **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 05 July 2025]

https://www.glopid-r.org/ Website not responding at inquiry.

**Hilleman Laboratories** [to 05 July 2025]

http://www.hilleman-labs.org/ News & Insights No new digest content identified.

## **HHMI - Howard Hughes Medical Institute** [to 05 July 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

## **Human Immunome Project [nee Human Vaccines Project]** [to 05 July 2025]

https://www.humanimmunomeproject.org/

News

## **Advances in Systems Immunology and Machine Learning**

The convergence of advanced immune monitoring technologies and artificial intelligence, particularly machine learning, is creating unprecedented opportunities to decode human immunity. In a comprehensive review published in the Annual Review of Immunology in April 2025, "Systems Human Immunology and AI: Immune Setpoint and Immune Health," Yona Lei and HIP Co-Chief Science Officer John Tsang review and provide perspectives...
July 3, 2025

**IAVI** [to 05 July 2025] https://www.iavi.org/ Press Releases, Features No new digest content identified.

**INSERM** [to 05 July 2025] https://www.inserm.fr/en/home/Press Releases
No new digest content identified.

#### International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 05 July 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selected]

Ongoing Public Consultations			
>	M11 EWG	Clinical electronic Structured Harmonised Protocol (CeSHarP)	
>	M13B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
>	Q1 EWG	Stability Testing of Drug Substances and Drug Products	
>	> M4Q(R2) EWG Revision of M4Q(R1)		
>	E21 EWG	Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials	

https://www.ich.org/page/public-consultations

ICRC [to 05 July 2025]
<a href="https://www.icrc.org/en/news">https://www.icrc.org/en/news</a>
Latest press releases and statements [Selected]
Article 01-07-2025
International Humanitarian Law Bibliography

IFFIm [to 05 July 2025] http://www.iffim.org/ Press Releases/Announcements No new digest content identified.

**IFRC** [to 05 July 2025] http://media.ifrc.org/ifrc/news/press-releases/ *Press releases* 04/07/2025

IFRC mourns the killing of five Iranian Red Crescent colleagues

Press release 03/07/2025

<u>Myanmar Earthquakes – 100 Days On</u>

Press release 30/06/2025

<u>IFRC calls for increased international support as Afghan population movement from Iran intensifies</u>

## **IPPS - International Pandemic Preparedness Secretariat** [to 05 July 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

**Institut Pasteur** [to 05 July 2025] https://www.pasteur.fr/en/press-area *Press Documents* 

Press release 04.06.2025

<u>Vigilance and targeted public health measures are essential in the face of the diphtheria epidemic that has affected vulnerable populations in Western Europe since 2022</u>

A study published in the New England Journal of Medicine (NEJM) reveals that the largest diphtheria epidemic in Western...

## **ISC / International Science Council** [to 05 July 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

blog

30 June 2025

## Five years from 2030: aligning knowledge and action on sustainability

As the world moves into the final stretch of the 2030 Agenda, the International Science Council (ISC) and the World Federation of Engineering Organizations (WFEO) call on governments, funders, and multilateral institutions to strengthen the systems that connect science and engineering with decision-making – and to ensure that all forms of knowledge are not only produced, but protected and leveraged to shape more sustainable, inclusive futures.

## **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected]

## 19th International Congress of Immunology

Vienna, August 17-22, 2025.

**IVAC** [to 05 July 2025]

https://www.ihsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events U.S. Measles Tracker

**Tracking Measles Cases in the U.S.** 

Updated July 5, 2025

IVI [to 05 July 2025] http://www.ivi.int/ IVI News & Announcements No new digest content identified.

## **Johns Hopkins Center for Health Security** [to 05 July 2025]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

## MSF/Médecins Sans Frontières [to 05 July 2025]

http://www.msf.org/ Latest [Selected Announcements] Afghanistan

Pressure grows on hospitals in Afghanistan as the numbers of paediatric patients rise

Project Update 4 Jul 2025

**Palestine** 

<u>Five months after start of Israeli military operation, humanitarian needs escalate in the West Bank</u>

Press Release 1 Jul 2025

## National Academy of Medicine - USA [to 05 July 2025]

https://nam.edu/programs/
News [Selected]
No new digest content identified.

## National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 05 July 2025]

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

**PATH** [to 05 July 2025]

https://www.path.org/media-center/

Newsroom [Selected]

New trial in Nigeria evaluates voice-based hotline that connects rural health care workers to the power of generative AI

July 1, 2025 by PATH

Community health extension workers are testing the performance of a toll-free platform that uses large language models to deliver on-demand, expert-level responses to their diagnosis and treatment questions.

## Sabin Vaccine Institute [to 05 July 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

**UNAIDS** [to 05 July 2025]

http://www.unaids.org/en

News, Stories, Updates

Press Release

<u>UNAIDS</u> welcomes the outcome of the 4th International Conference on Financing for Development and the ambition of the Seville Platform for Action for global health, debt restructuring and fair taxation

GENEVA/SEVILLE, 2 July 2025—At the 4th International Conference on Financing for Development, UNAIDS has welcomed the Financing for Development outcome document adopted by 192 countries in a time of multilateral distress. The new Seville Platform For Action calls for actionable and coordinated global efforts to transform and strengthen global health architecture, to advance debt restructuring, strengthen tax authorities and enable more progressive taxation of the wealthy and corporations...

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements [Selected]

Press release 01 July 2025

**Every five seconds, a child is displaced, injured, or killed in the Middle East and North Africa's conflicts** 

AMMAN, 1 July 2025 –, At least 12.2 million children have reportedly been killed, maimed or displaced in conflicts in the Middle East and North Africa (MENA) in less than 2 years, the equivalent of one child displaced every five seconds, and one child killed or maimed every fifteen minutes. Reports indicate over ...

Unitaid [to 05 July 2025]

https://unitaid.org/

News

News releases

<u>Unitaid and Japan's Nikkiso partner with Kenya and Tanzania to build liquid medical oxygen facilities in East Africa</u>

02 July 2025

News releases

<u>Unitaid welcomes new air levy coalition, building on its legacy of successful innovative health financing</u>

02 July 2025

## **Vaccine Equity Cooperative [nee Initiative]** [to 05 July 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

## Vaccine Confidence Project [to 05 July 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

## **Vaccine Education Center – Children's Hospital of Philadelphia** [to 05 July 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

Vaccine Update Newsletter June 2025

## June/July 2025: Thimerosal in Multidose Vaccine Vials: Then and Now

Dr. Paul Offit talks about the history of thimerosal in vaccines. You'll also find resources related to COVID-19 vaccines, measles outbreaks, and the June ACIP meeting.

Wellcome Trust [to 05 July 2025]

https://wellcome.org/news/all
News. Opinion, Reports
Analysis
Author Fabian Moser

## Why challenging global health funding cuts are an opportunity for reform

2 July 2025 6-minute read

Global health financing is under increasing strain, made more uncertain by a rapidly changing geopolitical situation. Dr Fabian Moser, Policy Adviser at Wellcome, analyses the urgent need to reform the global health architecture to ensure it is effective in a changing world....

Looking ahead

The collective response to this opportunity for reform would benefit from:

- ensuring country voices, priorities and leadership drive the conversation and decision-making around the future global health architecture
- prioritising coherence as global health financing discussions increase, it will be critical to think and act holistically, uniting everyone involved behind common and ambitious priorities
- involving finance leaders from the outset, strengthening the often-neglected link between the health and finance sectors
- delivering a rapid response with a long-term, inclusive perspective, where locally led analysis from all regions informs a globally representative new system

## **The Wistar Institute** [to 05 July 2025]

https://www.wistar.org/news/press-releases

Press Releases

June 30, 2025

## The Wistar Institute Announces the Appointment of Qingsheng Li, Ph.D., to HIV Cure and Viral Diseases Center

The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Qingsheng Li, Ph.D., as professor in the HIV Cure and Viral Diseases Center...

World Bank [to 05 July 2025] http://www.worldbank.org/en/news/all All News [Selected] No new digest content identified.

## WFPHA: World Federation of Public Health Associations [to 05 July 2025]

https://www.wfpha.org/ Blog, Events No new digest content identified.

## World Medical Association [WMA] [to 05 July 2025]

https://www.wma.net/news-press/press-releases/ Press Releases No new digest content identified.

## World Organisation for Animal Health [OIE] [to 05 July 2025]

https://www.oie.int/ Press Releases, Statements Statements

Statement on recent lumpy skin disease outbreaks in Europe

Published on 3 July 2025

The World Organisation for Animal Health (WOAH) acknowledges the rapid official notifications of two outbreaks of <a href="Lumpy skin disease"><u>Lumpy skin disease (LSD)</u></a> in Italy and France, as well as the details provided through their <a href="follow up">follow up</a> reports. This marks the first-ever occurrence of the disease in these countries, highlighting the urgent need for heightened surveillance and coordinated response. Both countries have reported that they are already implementing measures to contain the disease in line with international standards.

From 2016 to 2024, WOAH with the Food and Agriculture Organization of the United Nations and the European Union, supported the coordination of a <u>standing group of expert for LSD</u> in South-East Europe until the disease was successfully eradicated, thanks to effective vaccination and regional coordination. WOAH also continues to monitor the epidemiological situation in Africa, where the disease is endemic, as well as in the Middle East and <u>Asia.</u>

LSD is a highly contagious vector-borne viral disease that primarily affects cattle, water buffaloes and certain wild ruminants. Beyond its impact on animal health and welfare, LSD can cause significant economic losses for farmers due to reduced milk production, weight loss and reproductive impairment.

The **disease is not zoonotic** and therefore does not pose a threat to human health neither by direct contact with infected animals nor through the consumption of animal products from infected animals such as milk or meat...

::::::

## **ARM [Alliance for Regenerative Medicine]** [to 05 July 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest announcements identified.

**BIO** [to 05 July 2025]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

## **DCVMN – Developing Country Vaccine Manufacturers Network** [to 05 July 2025]

http://www.dcvmn.org/ News; Upcoming events No new digest announcements identified.

#### ICBA - International Council of Biotechnology Associations [to 05 July 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

**IFPMA** [to 05 July 2025]

https://ifpma.org/

News, Statements [Selected]

No new digest announcements identified.

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

## **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [to 05 July 2025] http://www.phrma.org/ Press Releases No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

#### **AstraZeneca**

<u>Press Releases</u> - No new digest announcements identified.

#### **Bavarian Nordic**

<u>Latest News</u> - No new digest announcements identified.

**BioCubaFarma** – Cuba

<u>Últimas Noticias</u> - No new digest announcements identified.

#### **Biological E**

News

## **BIOLOGICAL E. LIMITED & RECBIO COLLABORATE TO PRODUCE HPV9 VACCINE**

- :: Recbio to complete technology transfer
- :: BE to manufacture HPV9 vaccine for India, UNICEF and PAHO tender markets
- :: The HPV9 vaccine is a specially made vaccine that protects against nine types of Human Papillomavirus

Hyderabad, June 30, 2025: Jiangsu Recbio Technology Company Limited (02179.HK), a leading Chinese biopharmaceutical company, today announced that they have entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent HPV (HPV9) vaccine, REC603, to Biological E. Limited (BE), a leading Indian vaccine and pharmaceutical company. Recbio will provide BE with Drug Substance (DS) and transfer technology to formulate, fill, and package vaccines. It will also include technology transfer for DS production at an appropriate time in the future.

## **BioNTech**

<u>Press Releases</u> - No new digest announcements identified.

#### **Boehringer**

<u>Press Releases</u> - No new digest announcements identified.

#### **CanSinoBIO**

News - Website not responding at inquiry.

#### **CIGB**

Latest News - No new digest announcements identified.

#### CinnaGen

<u>Recent News</u> - Websiyte not responding at inquiry.

## Clover Biopharmaceuticals - China

<u>News</u> - No new digest announcements identified.

#### Curevac

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

#### **GSK**

<u>Press releases for media</u> - No new digest announcements identified.

## EuBiologics, S Korea

News - No new digest announcements identified.

#### IMBCAMS, China

<u>Home</u> - Website not responding at inquiry.

#### JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

#### Merck

<u>News releases</u> - No new digest announcements identified.

#### Moderna

Press Releases

June 30, 2025

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

#### Nanogen

News - No new digest announcements identified.

#### **Novartis**

News - No new digest announcements identified.

#### Novavax

<u>Press Releases</u> - No new digest announcements identified.

#### **Pfizer**

Recent Press Releases - No new digest announcements identified.

#### **R-Pharm**

https://rpharm-us.com/index.php
[No news or media page identified]

#### Sanofi Pasteur

<u>Press Releases</u> - No new digest announcements identified.

#### **Serum Institute**

News & Announcements

## Construction begins on state-of-the-art research facility

27 Jun 2025

The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford's mission to counter and constrain global health threats.

## Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified.

#### **Sinovac**

<u>Press Releases</u> - No new digest announcements identified.

#### **SK Biosciences**

Press Releases

SK bioscience Celebrates Completion of New Vaccine Production Facility for Global Market, Advancing Partnership with Sanofi

Large-scale production facility completed for GBP410, a 21-valent pneumococcal conjugate vaccine can...

2025.06.30

#### **Takeda**

<u>Newsroom</u> - No new digest announcements identified.

#### **Valneva**

<u>Press Releases</u> - No new digest announcements identified.

#### **Vector State Research Centre of Viralogy and Biotechnology**

<u>Home</u> - [Website not responding [404 error]]

#### WestVac Biopharma

Media - No new digest announcements identified.

### Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch

:: <u>Pre-Print Servers</u>

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

## **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 2 Jul 2025

https://journalofethics.ama-assn.org/issue/rural-us-emergency-medical-services

#### **AMA Journal of Ethics**

Volume 27, Number 7: E479-540

https://journalofethics.ama-assn.org/issue/embodiment-art-practice

## Rural US Emergency Medical Services

Emergency medical services (EMS) are the most immediate health care resource for many US residents living in rural areas. We all rely on EMS to coordinate deployment of networks of transporters, first-responders, basic and intermediate emergency medical technicians, paramedics, and medical directors. These clinicians bring professional skill sets and scopes of practice to their crews when our health needs are urgent. Yet, low call volume in rural areas hinders responders' exposure to real-life procedures and undermines reimbursement for services rendered, so many rural EMS programs must depend—and perhaps overly rely—on volunteers. Air transport and telehealth help some rural US residents overcome some proximity demands but are imperfect workarounds for meeting critical vulnerabilities and do not substantially mitigate rural/urban emergent care access inequity. This theme issue explores rural EMS as a source of clinical, legal, and policy-level questions neglected in health care ethics, policy, and equity discussions.

#### **American Journal of Human Genetics**

Jul 03, 2025 Volume 112 Issue 7 p1497-1732

https://www.cell.com/ajhg/current

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Newborn screening (NBS) contributes to reduced newborn morbidity and mortality globally. While reducing morbidity and mortality is already a public health success, the need for expanded and more widely adopted NBS initiatives is emphasized by the United Nations' goal to end preventable deaths of newborns and children under five years old by 2030. Incorporating genomic sequencing into NBS programs would enable earlier identification of a wide range of conditions, pushing us closer to this goal. Indeed, the value of including genomic sequencing in NBS programs is well recognized in the medical community, but an important component of ensuring successful implementation of such programs is understanding public values.

#### **American Journal of Infection Control**

June 2025 Volume 53 Issue 6 p669-746 <a href="http://www.ajicjournal.org/current">http://www.ajicjournal.org/current</a> [Reviewed earlier]

#### **American Journal of Preventive Medicine**

May 2025 Volume 68 Issue 5 p859-1050 <a href="https://www.ajpmonline.org/current">https://www.ajpmonline.org/current</a> [Reviewed earlier]

### **American Journal of Public Health**

June 2025 115(6) <a href="http://ajph.aphapublications.org/toc/ajph/current">http://ajph.aphapublications.org/toc/ajph/current</a> [Reviewed earlier]

## **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 6 (Jun 2025) <a href="https://www.ajtmh.org/view/journals/tpmd/112/6/tpmd.112.issue-6.xml">https://www.ajtmh.org/view/journals/tpmd/112/6/tpmd.112.issue-6.xml</a> [Reviewed earlier]

#### **Annals of Internal Medicine**

June 2025 Volume 178, Issue 6 https://www.acpjournals.org/toc/aim/current [Reviewed earlier]

## **Artificial Intelligence – An International Journal**

Volume 344 July 2025 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/344/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/344/suppl/C</a> [Reviewed earlier]

#### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 05 July 2025) [No new digest content identified]

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 05 July 2025

<u>Cost-effectiveness and benefit-risk of rotavirus vaccination in Afghanistan: a modelling</u> analysis informed by post-licensure surveillance

Afghanistan added ROTARIX to the routine national immunization programme in 2018. We aimed to estimate the cost-effectiveness and benefit-risk of ROTARIX and compare its continued use with other rotavirus vacc...

Authors: Palwasha Anwari, Frédéric Debellut, Sardar Parwiz, Clint Pecenka and Andrew Clark

Citation: *BMC Health Services Research* 2025 25:926 Content type: Research Published on: 4 July 2025

## Bridging the digital divide: Understanding COVID-19 diagnostic and vaccination experiences in a socioeconomically disadvantaged neighborhood in Sweden

The COVID-19 pandemic had a significant impact on the public health and the economy of the Swedish population, with disproportionate effects on communities living in socioeconomically diverse neighborhoods. To...

Authors: Rathi Ramji, Dipak Surie, Stefan Cirovic, Margareta Rämgård, Sergey Shleev and Anders

Kottorp

Citation: *BMC Health Services Research* 2025 25:870 Content type: Research Published on: 1 July 2025

## **Decolonizing global health: a scoping review**

We summarize research on decolonizing global health and highlight existing gaps, including the lack of a formal definition and clear aims for the movement. We examine the decolonization of global health curric...

Authors: Deena Mehjabeen, Kyle Patel and Rahul M. Jindal

Citation: BMC Health Services Research 2025 25:828

Content type: Systematic Review Published on: 1 July 2025

#### **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 05 July 2025)

## <u>Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: a systematic review and meta-analysis</u>

This study aimed to synthesize existing evidence to compare the immunogenicity and safety of domestic and imported live-attenuated varicella vaccine (VarV) in healthy Chinese populations.

Authors: Yemin Yuan, Tong Wang, Yigi Xia, Zhenyu Shi and Ping He

Citation: BMC Infectious Diseases 2025 25:897

Content type: Systematic Review Published on: 5 July 2025

## <u>The delivery of new tuberculosis vaccines to people living with HIV – when to vaccinate?</u>

Tuberculosis (TB) remains a major cause of morbidity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PL...

Authors: Tom Sumner, Rebecca A. Clark, Tomos O. Prys-Jones, Roel Bakker, Gavin Churchyard and

Richard G. White

Citation: BMC Infectious Diseases 2025 25:878 Content type: Research Published on: 1 July 2025

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 05 July 2025)

How participation in deliberative engagement affects awareness of, and attitudes towards, genomics research and data sharing: evidence from rural Ghana

Deliberative engagement offers an opportunity for communities to provide informed opinions on complex ethical, legal, and social issues in genomic research and biobanking. However, its use is limited, particul...

Authors: Irene Honam Tsey, Pamela Emefa Selormey, John Ganle, Patricia Akweongo and Paulina

Tindana

Citation: BMC Medical Ethics 2025 26:87

Content type: Research Published on: 4 July 2025

## Returning of individual genetic findings to biobank participants: a mixed methods study results in Lithuania

There is an ongoing global debate regarding the return of individual genetic findings (IGF) in the field of biobanking. Various models for returning these findings are actively discussed, and strategies for th...

Authors: Jūratė Lekstutienė, Rūta Žiliukaitė, Marija Jakubauskienė and Eugenijus Gefenas

Citation: BMC Medical Ethics 2025 26:86

Content type: Research Published on: 4 July 2025

## <u>Descriptions of risks and benefits of HIV vaccine trials in low-and middle-income countries</u> (LMICs): an integrative review

Human immunodeficiency virus (HIV) vaccine trials are needed in efforts to prevent infection and acquired immunodeficiency syndrome (AIDS). Like other types of research, HIV vaccine trials present benefits and...

Authors: Judith Shayo, Deodatus Sabas, Adamu Addissie, Eligius Lyamuya and Connie Ulrich

Citation: BMC Medical Ethics 2025 26:75

Content type: Systematic Review Published on: 3 July 2025

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 05 July 2025) [No new digest content identified]

### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 05 July 2025) No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 05 July 2025)

<u>Comparative effectiveness and immunogenicity of single-dose and multi-dose human</u> papillomavirus vaccination: a systematic review

Administering a single dose of the human papillomavirus vaccine substantially reduces costs and simplifies distribution. However, due to inconsistent findings in the existing research, there is an ongoing deba...

Authors: Meeyeong Jeong and Insil Jang Citation: *BMC Public Health* 2025 25:2330

Content type: Systematic Review Published on: 3 July 2025

<u>Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial</u>

Seasonal influenza poses an enormous burden worldwide, with older adults facing preventable morbidity and mortality. However, seasonal influenza vaccination coverage is poor among older populations in China. P...

Authors: Qing-Qing Li, Zizhen Huang, Jiangyun Chen, Junjie Wang, Duqiao Li, Xiaoshan Chen, Qing Zhao, Siyuan Liu, Wenjun He, Huanyuan Luo, Yuting Wan, Guangyu Tong, Dexing Zhang, Yiyuan Cai, Huijuan Liang, Dan Wu...

Citation: BMC Public Health 2025 25:2372

Content type: Study Protocol Published on: 3 July 2025

## <u>Inequalities in full immunization coverage among one-year-olds in the Democratic</u> Republic of the Congo, 2007–2017

The Democratic Republic of the Congo (DRC) ranks among the top ten countries with the highest rates of zero-dose or partially immunized children. However, there is limited knowledge about the extent of inequal...

Authors: Etienne Mwokozi Bwira, Théophane Kekemb Bukele, Paulin Beya Mutombo, John Kebela

Kamwina and Dosithée Bebe Ngo

Citation: BMC Public Health 2025 25:2354

Content type: Research Published on: 3 July 2025

## <u>Factors associated with parental acceptance of the HPV vaccine in girls from metropolitan</u> Lima, Peru

In 2022, cervical cancer was the second most common neoplasia among women in Peru, with 4809 cases and 2545 deaths reported. Infection with human papillomavirus (HPV) is a key factor in the development of this...

Authors: Valeria Juárez-Leon, Delahnie Calderón-Solano, Julio A. Poterico, Jorge Ybaseta-Medina, Diego

Azañedo and J. Smith Torres-Román

Citation: BMC Public Health 2025 25:2334

Content type: Research Published on: 3 July 2025

## <u>High immunisation coverage but sporadic outbreaks of vaccine-preventable diseases: the structural gaps in vaccination uptake in central highlands, Vietnam</u>

Despite the successful implementation of the Expanded Programme on Immunization (EPI) for the past three decades, Vietnam has recently witnessed outbreaks of vaccine-preventable diseases, indicating a potentia...

Authors: Thanh Ha Nguyen, Thi Phuoc Loan Mai, C. Louise Thwaites, Jennifer Ilo Van Nuil and Mary

Chambers

Citation: BMC Public Health 2025 25:2293

Content type: Research Published on: 3 July 2025

## Trust in doctors, social support, and belief in COVID-19 misinformation

Misinformation has emerged as a major concern for public health during the COVID-19 pandemic. Our study conceptualizes trust in doctors and social support through the lens of social capital theory and investig...

Authors: Urszula A. Horoszko, Lindsay Smith, Amy Murphy, Bruce G. Taylor, Phoebe A. Lamuda, Harold

A. Pollack, John A. Schneider, Faye S. Taxman and Xiaoquan Zhao

Citation: BMC Public Health 2025 25:2236

Content type: Research Published on: 2 July 2025

## Factors associated with parental literacy and hesitancy toward pediatric vaccination

Vaccine literacy (knowledge about vaccines and the ability to identify accurate information about them) and vaccine hesitancy (delay in or refusal of vaccination) among parents may affect immunization decision...

Authors: Yi Zheng, Paula M. Frew, Dong Wang and Amanda L. Eiden

Citation: BMC Public Health 2025 25:2201

Content type: Research Published on: 2 July 2025

#### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 05 July 2025) [No new digest content identified]

#### **BMJ Evidence-Based Medicine**

June 2025 - Volume 30 - 3 https://ebm.bmj.com/content/30/3 [Reviewed earlier]

#### **BMJ Global Health**

June 2025 - Volume 10 - 6 https://gh.bmj.com/content/10/6 [Reviewed earlier]

#### **Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - May 2025 https://thebulletin.org/magazine/2025-03/ [Reviewed earlier]

#### **Bulletin of the World Health Organization**

Volume 103, Number 6, June 2025, 349-412 <a href="https://www.who.int/publications/journals/bulletin/">https://www.who.int/publications/journals/bulletin/</a> [Reviewed earlier]

#### Cell

Jun 26, 2025 Volume 188 Issue 13 p3367-3624 <a href="https://www.cell.com/cell/current">https://www.cell.com/cell/current</a>
[New issue; No digest content identified]

## **Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4 <a href="https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4">https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4</a> [Reviewed earlier]

## **Child Care, Health and Development**

Volume 51, Issue 4 July 2025 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

# **Clinical Pharmacology & Therapeutics**

Volume 118, Issue 1 Pages: 1-271 July 2025 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> [Reviewed earlier]

# **Clinical Therapeutics**

June 2025 Volume 47 Issue 6 p403-462 <a href="http://www.clinicaltherapeutics.com/current">http://www.clinicaltherapeutics.com/current</a> [Reviewed earlier]

### **Clinical Trials**

Volume 22 Issue 3, June 2025 https://journals.sagepub.com/toc/ctja/22/3 Articles [Reviewed earlier]

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 05 July 2025] [No new digest content identified]

# **Contemporary Clinical Trials**

Volume 153 June 2025

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/153/suppl/C
[New issue; No digest content identified]

# The CRISPR Journal

Volume 8, Issue 3 / June 2025 https://www.liebertpub.com/toc/crispr/8/3 [Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025 <a href="https://link.springer.com/journal/40142/volumes-and-issues/13-1">https://link.springer.com/journal/40142/volumes-and-issues/13-1</a> [Reviewed earlier]

# **Current Medical Research and Opinion**

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

# **Current Opinion in Infectious Diseases**

June 2025 - Volume 38 - Issue 3

# https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 05 July 2025] [No new digest content identified]

# Cytotherapy

May 2025 Volume 27 Issue 5 p565-670 <a href="https://www.isct-cytotherapy.org/current">https://www.isct-cytotherapy.org/current</a> [Reviewed earlier]

# **Developing World Bioethics**

Volume 25, Issue 2 Pages: 81-163 June 2025 <a href="https://onlinelibrary.wiley.com/toc/14718847/current">https://onlinelibrary.wiley.com/toc/14718847/current</a> [Reviewed earlier]

#### **Development in Practice**

Volume 35, Issue 4, 2025 <a href="https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList">https://www.tandfonline.com/toc/cdip20/35/4?nav=tocList</a> [Reviewed earlier]

# **Development Policy Review**

Volume 43, Issue 4 July 2025 <a href="https://onlinelibrary.wiley.com/toc/14677679/current">https://onlinelibrary.wiley.com/toc/14677679/current</a> [Reviewed earlier]

# **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

#### **Disasters**

Volume 49, Issue 3 July 2025 <a href="https://onlinelibrary.wiley.com/toc/14677717/current">https://onlinelibrary.wiley.com/toc/14677717/current</a> [Reviewed earlier]

#### **eBioMedicine**

Volume 1166 May 2025 <a href="https://www.sciencedirect.com/journal/ebiomedicine/vol/116/suppl/C">https://www.sciencedirect.com/journal/ebiomedicine/vol/116/suppl/C</a> [Reviewed earlier]

#### **EMBO Reports**

Volume 26 Issue 1027 May 2025 <a href="https://www.embopress.org/toc/14693178/current">https://www.embopress.org/toc/14693178/current</a> [Reviewed earlier]

# **Emerging Infectious Diseases**

Volume 31, Number 5—May 2025 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [Reviewed earlier]

### **Epidemics**

Volume 51 June 2025 <a href="https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/51/suppl/C</a> [Reviewed earlier]

# **Epidemiology and Infection**

Volume 153 - 2025 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

#### **Ethics & Human Research**

Volume 47, Issue 3, Pages: 1-45, May–June 2025 <a href="https://onlinelibrary.wiley.com/toc/25782363/current">https://onlinelibrary.wiley.com/toc/25782363/current</a> **Undue inducement :: Deception in research** [Reviewed earlier]

#### **Ethics & International Affairs**

Volume 38 - Issue 4 - Winter 2024 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

#### **Ethics, Medicine and Public Health**

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

# The European Journal of Public Health

Volume 35, Issue 2, April 2025 <a href="https://academic.oup.com/eurpub/issue/35/2">https://academic.oup.com/eurpub/issue/35/2</a> [Reviewed earlier]

# **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

https://www.tandfonline.com/toc/ierv20/current

[Reviewed earlier]

# **Foreign Affairs**

May/June 2025 Volume 104, Number 3 <a href="https://www.foreignaffairs.com/issues/2025/104/3">https://www.foreignaffairs.com/issues/2025/104/3</a> [Reviewed earlier]

#### **Forum for Development Studies**

Volume 52, 2025 - Issue 2

http://www.tandfonline.com/toc/sfds20/current

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

# **Frontiers in Genetics**

https://www.frontiersin.org/journals/genetics [Accessed 05 July 2025] [No new digest content identified]

# **Frontiers in Genome Editing**

https://www.frontiersin.org/journals/genome-editing [Accessed 05 July 2025] [No new digest content identified]

#### **Frontiers in Medicine**

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463 [Accessed 05 July 2025] [No new digest content identified]

#### **Gene Therapy – Nature**

Volume 32 Issue 3, May 2025 https://www.nature.com/gt/volumes/32/issues/3 [Reviewed earlier]

# **Genetics in Medicines**

Volume 27, Issue 6 June 2025 <a href="https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65">https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65</a> [Reviewed earlier]

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 05 July 2025] [No new digest content identified]

## **Global Health Action**

Volume 18, Issue 1 (2025) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

# **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

### Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/ https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\_desc [Accessed 05 July 2025] [No new digest content identified]

# **Global Public Health**

Volume 20, Issue 1 (2025) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 05 July 2025] [No new digest content identified]

#### **Health and Human Rights**

Volume 26, Issue 2, December 2024 https://www.hhrjournal.org/volume-26-issue-2-december-2024/ **Special Section: Distress Migration and the Right to Health** [Reviewed earlier]

# **Health Economics, Policy and Law**

Volume 20 - Issue 1 - January 2025 <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue">https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</a> [Reviewed earlier]

#### **Health Policy and Planning**

Volume 40, Issue 5 June 2025 <a href="https://academic.oup.com/heapol/issue/40/5">https://academic.oup.com/heapol/issue/40/5</a> [Reviewed earlier]

# **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 05 July 2025] [No new digest content identified]

# **Human Gene Therapy**

Volume 36, Issue 13-14 / July 2025 <a href="https://www.liebertpub.com/toc/hum/36/13-14">https://www.liebertpub.com/toc/hum/36/13-14</a> [New issue; No digest content identified]

#### **Humanitarian Practice Network**

https://odihpn.org/
[Accessed 05 July 2025]
Featured Publications
[No new digest content identified]

# **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025 https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList Selected Content [Reviewed earlier]

#### **Immunity**

Jun 10, 2025 Volume 58 Issue 6 p1361-1614 <a href="https://www.cell.com/immunity/current">https://www.cell.com/immunity/current</a> Articles [Reviewed earlier]

# **Infectious Agents and Cancer**

http://www.infectagentscancer.com/ [Accessed 05 July 2025] [No new digest content identified]

#### **Infectious Diseases of Poverty**

http://www.idpjournal.com/content]
[Accessed 05 July 2025]
[No new digest content identified]

# **International Health**

Volume 17, Issue 4, July 2025 <a href="https://academic.oup.com/inthealth/issue/17/4">https://academic.oup.com/inthealth/issue/17/4</a> EDITOR'S CHOICE - Commentary

Left behind no more: ensuring equitable vaccine access to curb mpox in Africa Open Access

Obasanjo Bolarinwa and others Published: 22 March 2025 Mpox, a zoonotic viral disease caused by the mpox virus (MPXV), has been endemic in Central and West Africa for decades, with transmission historically linked to animal-to-human contact and limited human-to-human spread. However, the 2022–2023 outbreak of clade IIb marked a turning point, with rapid global transmission predominantly via sexual contact, particularly among men who have sex with men (MSM) in non-endemic regions. Unlike past outbreaks, which were largely ignored by the global health community due to their localized nature, this outbreak spread across Europe, North America and South America, prompting immediate public health interventions, including targeted vaccination campaigns using smallpox-derived vaccines.

Despite Africa's long-standing mpox burden, the response to this global outbreak once again exposed glaring inequalities in vaccine access. Countries in Europe and North America swiftly secured vaccines, leveraging their purchasing power and existing healthcare infrastructure, while African nations where mpox has been historically endemic were left behind.<sup>4</sup> As of August 2024, >106 310 mpox cases have been recorded across 123 World Health Organization (WHO) member states, including 234 deaths.<sup>5</sup> In Africa, 20 countries have reported cases, with the highest caseloads recorded in the Democratic Republic of the Congo (DRC), Burundi and Nigeria, yet vaccine access in these regions remains severely limited.<sup>5</sup> The persistent disparities in vaccine distribution reflect the deep-rooted inequities in global health governance, where resource allocation continues to favour wealthier nations over regions with the greatest disease burden. The continuous spread of the virus led the WHO to declare it a public health emergency of international concern (PHEIC) on 14 August 2024.<sup>6</sup> This declaration reinforces the urgent need for enhanced public health measures, particularly ensuring mpox vaccine equity, to curtail the increasing spread of the viral disease and minimize its burden globally.

# **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml

[Reviewed earlier]

# **International Journal of Community Medicine and Public Health**

Vol. 12 No. 5 (2025): May 2025

https://www.ijcmph.com/index.php/ijcmph/issue/view/124

[Reviewed earlier]

#### **International Journal of Epidemiology**

Volume 54, Issue 3, June 2025

https://academic.oup.com/ije/issue/54/3 [New issue; No digest content identified]

# **International Journal of Human Rights in Healthcare**

Volume 18 Issue 1 2025

https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1

Table of contents [Reviewed earlier]

### **JAMA**

July 1, 2025, Vol 334, No. 1, Pages 5-98

https://jamanetwork.com/journals/jama/currentissue

**Viewpoint** 

# <u>Long-Acting HIV Treatment in Low- and Middle-Income Countries - Addressing the Public</u> Health Need

Peter D. Ehrenkranz, MD; Michael J. A. Reid, MD; Meg Doherty, MD; et al.

JAMA. 2025;334(1):15-16. doi:10.1001/jama.2025.5180

This Viewpoint discusses the need to develop products, such as long-acting antiretrovirals, for people with HIV in settings with minimal resource requirements.

# Comment & Response

# **ICMJE Should Create a Certification System to Identify Predatory Journals**

Maximilian Siebert, PharmD, PhD; Florence T. Bourgeois, MD, MPH; Florian Naudet, MD, PhD JAMA. 2025;334(1):87-88. doi:10.1001/jama.2025.3661 *Editorial* 

**Predatory Journals-What Can We Do to Protect Their Prey?** 

#### **JAMA Health Forum**

July 2025, Vol 6, No. 7 https://jamanetwork.com/journals/jama-health-forum/issue [New issue; No digest content identified]

#### **JAMA Pediatrics**

June 2025, Vol 179, No. 6, Pages 587-688 <a href="https://jamanetwork.com/journals/jamapediatrics/currentissue">https://jamanetwork.com/journals/jamapediatrics/currentissue</a> [New issue; No digest content identified]

# **JBI Evidence Synthesis**

June 2025 - Volume 23 - Issue 6 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

#### **Journal of Adolescent Health**

July 2025 Volume 77 Issue 1 p1-172 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [Reviewed earlier]

#### **Journal of Artificial Intelligence Research**

Vol. 83 (2025) <a href="https://www.jair.org/index.php/jair">https://www.jair.org/index.php/jair</a>
[New issue; No digest content identified]

# **Journal of Bioethical Inquiry**

Volume 22, Issue 1 March 2025 https://link.springer.com/journal/11673/volumes-and-issues/22-1 https://link.springer.com/journal/10900/volumes-and-issues/50-3 [Reviewed earlier]

# **Journal of Community Health**

Volume 50, Issue 3 June 2025 <a href="https://link.springer.com/journal/10900/volumes-and-issues/50-3">https://link.springer.com/journal/10900/volumes-and-issues/50-3</a> [Reviewed earlier]

# **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

# **Journal of Development Economics**

Volume 176 September 2025 <a href="https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C">https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C</a> [Reviewed earlier]

# **Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 3, July 2025

http://journals.sagepub.com/toc/jre/current

Restricted access Research article First published May 13, 2025

<u>Perspectives of Research Ethics Committees on the Challenges of Human Genomic Research Participation in Ethiopia</u>

Herani Sahlu Dembu, et al.

**Abstract** 

Human Genomic Research (HGR) has contributed to public health advancement by identifying disease susceptibility and resistance. However, HGR is surrounded by several ethical, legal, and societal concerns. This qualitative research study explored the ...

# **Journal of Epidemiology & Community Health**

June 2025 - Volume 79 - 6 https://jech.bmj.com/content/79/6 [Reviewed earlier]

#### **Journal of Evidence-Based Medicine**

Volume 18, Issue 2 June 2025 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 21, Issue 1 (2025) http://www.tandfonline.com/toc/rjge20/current Review Article

<u>Co-existential justice and individual freedom: the primary concern and the normative foundation of global ethics</u>

An-ging Deng

Pages: 114-122 Published online: 10 Jan 2025

Review Article

The passing of another golden age: global ethics in a time of deglobalisation

Christopher Hobson

Pages: 123-132 Published online: 28 Mar 2025

Review Article

Ethics for a breaking world: capabilities, intervention, responsibility, impartiality

Oscar A. Gómez Pages: 133-145

Published online: 31 Mar 2025

# Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 2, May 2025 <a href="https://muse.jhu.edu/issue/54734">https://muse.jhu.edu/issue/54734</a> <a href="Table of Contents">Table of Contents</a> <a href="Reviewed earlier">[Reviewed earlier</a>]

#### **Journal of Immigrant and Minority Health**

Volume 27, Issue 3 June 2025 <a href="https://link.springer.com/journal/10903/volumes-and-issues/27-3">https://link.springer.com/journal/10903/volumes-and-issues/27-3</a> [Reviewed earlier]

#### **Journal of Immigrant & Refugee Studies**

Volume 23, Issue 2 (2025) <a href="https://www.tandfonline.com/toc/wimm20/current">https://www.tandfonline.com/toc/wimm20/current</a> [Reviewed earlier]

#### **Journal of International Development**

Volume 37, Issue 4 pages: 1-1053 May 2025 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

#### **Journal of Medical Ethics**

June 2025 - Volume 51 - 6 http://jme.bmj.com/content/current [Reviewed earlier]

# **Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 1 (2025) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

#### The Journal of Pediatrics

Volume 282 July 2025 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/282/suppl/C</a> [Reviewed earlier]

# **Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1 <a href="https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList">https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList</a> [Reviewed earlier]

#### **Journal of Public Health Management & Practice**

July/August 2025 - Volume 31 - Issue 4 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

# **Journal of Public Health Policy**

Volume 46, Issue 2 June 2025 <a href="https://link.springer.com/journal/41271/volumes-and-issues/46-2">https://link.springer.com/journal/41271/volumes-and-issues/46-2</a> [Reviewed earlier]

# Journal of the Royal Society - Interface

July 2025 Volume 22 Issue 228 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> Review articles

Advantages of using complement components in preventive and therapeutic vaccine strategies for infectious and non-infectious diseases

<u>Nur Hendri Wahyu Firdaus</u>, <u>Buddhadev Mallick</u>, <u>Kutty Selva Nandakumar</u> and <u>Akhilesh Kumar Shakya</u> Published:02 July 2025Article ID:20250138 <a href="https://doi.org/10.1098/rsif.2025.0138">https://doi.org/10.1098/rsif.2025.0138</a>

#### **Journal of Travel Medicine**

Volume 32, Issue 5, July 2025 https://academic.oup.com/jtm/issue Editor's Choice

#### Re-imagining combination vaccines for travel medicine

Sarah L McGuinness and others

Vaccines are amongst the greatest innovations in public health. Since the launch of the World Health Organization's (WHO) Expanded Programme on Immunization (EPI) in 1974, vaccines have saved an estimated 154 million lives from 14 different diseases, particularly amongst children under five. ¹ The pace of vaccine development has accelerated dramatically, increasing from three to four novel vaccines per decade in the late 20th century to ≥15 novel vaccines already in the 21st century (Table 1).³,⁴ This surge has expanded protection against a wider array of diseases but has also resulted in overcrowded immunization schedules and increased demand on public and private healthcare providers, including travel clinics. As an example, a child in a low- and middle-income country (LMIC) may currently receive 18 vaccines by injection and seven oral doses at nine visits to protect against 15 diseases. With the rapid progress in novel vaccine availability, this could increase in the foreseeable future to 29 injections and seven oral doses at 12 visits, protecting against 19 diseases, a scenario that is not operationally

feasible nor likely to be accepted by caretakers and children. However, combining existing and novel antigens into combination vaccines could reduce this to 16 injections at nine visits and protect against 22 diseases.<sup>5</sup>

Editor's Choice

# A new non-live chikungunya vaccine for travellers

David O Freedman

https://doi.org/10.1093/jtm/taaf039

Chikungunya virus-like particle, a single dose non-live vaccine provides > 95% overall short-term seroresponse rates in robust trials in potential travellers to endemic areas with onset of sero-protection that may be as short as 8 days. Vaccination is recommended for travel to outbreak areas and for extended travel (≥6 months) to areas with CDC (Centers for Disease Control and Prevention) designated risk.

# **Journal of Virology**

Volume 99 • Number 6 • June 2025 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [New issue; No digest content identified]

#### The Lancet

Jul 05, 2025 Volume 406 Number 10498 p1-102 https://www.thelancet.com/journals/lancet/issue/current Comment

# Africa's renaissance amid declining overseas health aid

Nelson K Sewankambo, Hossein Akbarialiabad, Serigne Magueye Gueye, Sabrina Bakeera-Kitaka, Judy N Khanyola, Kiguli-Malwadde Elsie, Chiratidzo E Ndhlovu, Bruce Kirenga, Abigail Kazembe, Prisca Olabisi Adejumo, Majid Sadigh, Mosa Moshabela

Many African countries have long relied on overseas development aid to implement health programmes. Unfortunately, this aid has fostered dependency and fragmentation, often introducing vertical programmes that operate parallel to government plans. The USA, historically the largest provider of such support (which contributes to the maintenance of the USA's soft power in Africa) has taken a sudden and chaotic U-turn, drastically reducing aid and restructuring or dismantling the institutions responsible for its implementation.¹ For example, the United States Agency for International Development was dismantled in a matter of weeks.².² Similarly, the UK and EU countries have also planned to reduce overseas aid spending.

Online First, July 01, 2025 Comment

# **Building a resistance to US assaults on public health**

Alicia Ely Yamina,b ayamin@pih.org · Emma Joanna Lenglec,d · Gregg Gonsalvese a Partners In Health, Boston, MA, USA bHarvard Law School, Cambridge, MA 02138, USA cHarvard Medical School, Boston, MA, USA dInstitute of Health and Society, University of Oslo, Oslo, Norway eYale School of Public Health, New Haven, CT, USA

The administration of US President Donald Trump has launched a full-fledged assault on science and public health; its "flood the zone" strategy created chaos and initially overwhelmed potential opposition. Yet drawing on the leadership of long-time health activists in areas such as HIV/AIDS, women's and LGBTQIA+ health, and disability, racial, and climate justice, as well as the creativity of youth leaders, organisations, labour unions, and grass-roots movements are re-enlivening existing

networks and creating new ones to bridge agendas, pressure institutions, and build advocacy power in support of public health. Defend Public Health, for example, was established shortly after Trump's reelection and now organises more than 3000 volunteers from across the country to share information and strategies and to take concrete actions, such as blocking the nomination of Dave Weldon to head the US Centers for Disease Control and Prevention (CDC) and opposing proposed Medicaid and other cuts. 3

#### The Lancet Child & Adolescent Health

Jun 2025 Volume 9 Number 6 p361-438, e14 <a href="https://www.thelancet.com/journals/lanchi/issue/current">https://www.thelancet.com/journals/lanchi/issue/current</a> [Reviewed earlier]

# **Lancet Digital Health**

Jun 2025 Volume 7 Number 6 https://www.thelancet.com/journals/landig/issue/current Health Policy

<u>Transforming women's health, empowerment, and gender equality with digital health:</u> evidence-based policy and practice

Israel Júnior Borges do Nascimento, et al. *Summary* 

We evaluated the effects of digital health technologies (DHTs) on women's health, empowerment, and gender equality, using the scoping review method. Following a search across five databases and grey literature, we analysed 80 studies published up to Aug 18, 2023. The thematic appraisal and quantitative analysis found that DHTs positively affect women's access to health-care services, self-care, and tailored self-monitoring enabling the acquisition of health-related interventions. Use of these technologies is beneficial across various medical fields, including gynaecology, endocrinology, and psychiatry. DHTs also improve women's empowerment and gender equality by facilitating skills acquisition, health education, and social interaction, while allowing cost-effective health services. Overall, DHTs contribute to better health outcomes for women and support the UN Sustainable Development Goals by improving access to health care and financial literacy.

# **Lancet Global Health**

Jun 2025 Volume 13 Number 6 e974-e1150 <a href="https://www.thelancet.com/journals/langlo/issue/current">https://www.thelancet.com/journals/langlo/issue/current</a> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Jun 2025 Volume 25 Number 6 p595-700, e316-e369 <a href="https://www.thelancet.com/journals/laninf/issue/current">https://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

#### **Lancet Public Health**

Jun 2025 Volume 10 Number 6 e433-e536 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [Reviewed earlier]

# **Lancet Respiratory Medicine**

Jun 2025 Volume 13 Number 6 p473-568, e30-e32 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [Reviewed earlier]

#### **Maternal and Child Health Journal**

Volume 29, Issue 6 June 2025 <a href="https://link.springer.com/journal/10995/volumes-and-issues/29-6">https://link.springer.com/journal/10995/volumes-and-issues/29-6</a> [Reviewed earlier]

# **Medical Decision Making (MDM)**

Volume 45 Issue 5, July 2025 <a href="http://mdm.sagepub.com/content/current">http://mdm.sagepub.com/content/current</a> [Reviewed earlier]

#### **The Milbank Quarterly**

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 2 Pages: 243-637 June 2025 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [New issue; No digest content identified]

# **Molecular Therapy**

Jul 02, 2025 Volume 33 Issue 7 p2951-3452 <a href="https://www.cell.com/molecular-therapy/current">https://www.cell.com/molecular-therapy/current</a> [New issue; No digest content identified]

# **Nature**

Volume 643 Issue 8070, 3 July 2025 https://www.nature.com/nature/volumes/641/issues/8070 Editorial 01 Jul 2025

#### **Transparent research: can big tech learn from big pharma?**

The results of technology research and development must find their way into the published literature. New models of regulation could help.

#### **Nature Biotechnology**

Volume 43 Issue 6, June 2025 <a href="https://www.nature.com/nbt/volumes/43/issues/6">https://www.nature.com/nbt/volumes/43/issues/6</a> [Reviewed earlier]

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 05 July 2025) [Reviewed earlier]

#### **Nature Genetics**

Volume 57 Issue 6, June 2025 <a href="https://www.nature.com/ng/volumes/57/issues/6">https://www.nature.com/ng/volumes/57/issues/6</a> [Reviewed earlier]

#### **Nature Human Behaviour**

Volume 9 Issue 6, June 2025 <a href="https://www.nature.com/nathumbehav/volumes/9/issues/6">https://www.nature.com/nathumbehav/volumes/9/issues/6</a> [Reviewed earlier]

#### **Nature Medicine**

Volume 31 Issue 6, June 2025 <a href="https://www.nature.com/nm/volumes/31/issues/6">https://www.nature.com/nm/volumes/31/issues/6</a> [Reviewed earlier]

#### **Nature Reviews Drug Discovery**

Volume 24 Issue 6, June 2025 <a href="https://www.nature.com/nrd/volumes/24/issues/6">https://www.nature.com/nrd/volumes/24/issues/6</a> [Reviewed earlier]

#### **Nature Reviews Genetics**

Volume 26 Issue 7, July 2025 https://www.nature.com/nrg/volumes/26/issues/7 Comment 10 May 2025

#### Challenges and solutions to the sustainability of gene and cell therapies

Despite their immense potential, gene and cell therapies that target rare diseases are at risk of market withdrawal, owing to several challenges. The authors describe these hurdles and call for innovative measures to improve the economic sustainability of gene and cell therapies after regulatory approval. Celeste Scotti, Alessandro Aiuti, Luigi Naldini

#### **Nature Reviews Immunology**

Volume 25 Issue 6, June 2025 https://www.nature.com/nri/volumes/25/issues/6 World View 07 May 2025 [Reviewed earlier]

# **New England Journal of Medicine**

Volume 393 No. 1 July 3, 2025 <a href="https://www.nejm.org/toc/nejm/medical-journal">https://www.nejm.org/toc/nejm/medical-journal</a> [New issue; No digest content identified]

# **NEJM Evidence**

Volume 4 No. 7 July 2025 https://evidence.nejm.org/toc/evid/current NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

# njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 05 July 2025] [No new digest content identified]

#### **Pediatrics**

Volume 156, Issue 1 July 2025 https://publications.aap.org/pediatrics/issue/156/1 Pediatrics Perspectives

**Vaccines Matter: Measles and Its Complications** 

Christopher Kuo, MD

#### **PharmacoEconomics**

Volume 43, Issue 6 June 2025 <a href="https://link.springer.com/journal/40273/volumes-and-issues/43-6">https://link.springer.com/journal/40273/volumes-and-issues/43-6</a> [Reviewed earlier]

# **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 05 July 2025) [No new digest content identified]

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 05 July 2025) [No new digest content identified]

#### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\_NEWEST\_FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 05 July 2025) [No new digest content identified]

#### **PLoS Medicine**

https://journals.plos.org/plosmedicine/ (Accessed 05 July 2025)

The potential global health impact and cost-effectiveness of next-generation influenza vaccines: A modelling analysis

Lucy Goodfellow, Simon R Procter, Mihaly Koltai, Naomi R. Waterlow, Johnny A. N. Filipe, Carlos K. H. Wong, Edwin van Leeuwen, Rosalind M. Eggo, Mark Jit, for the WHO Technical Advisory Group for the

Full Value of Influenza Vaccines Assessment and project team , Next-generation influenza vaccine impact modelling contributors

Research Article | published 30 Jun 2025 PLOS Medicine

https://doi.org/10.1371/journal.pmed.1004655

# **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 05 July 2025) [No new digest content identified]

#### **PLoS One**

http://www.plosone.org/ [Accessed 05 July 2025]

<u>Measles vaccines and non-specific effects on mortality or morbidity: A systematic review</u> and meta-analysis

Louise A. Fournais, Anne C. Zimakoff, Andreas Jensen, Jeppe H. Svanholm, Ingvild Fosse, Lone G. Stensballe

Research Article | published 02 Jul 2025 PLOS ONE

https://doi.org/10.1371/journal.pone.0321982

#### Vulnerability in research ethics: A systematic review of policy guidelines and documents

Asia Grigis, Giorgia Beretta, Pascal Borry, Virginia Sanchini Research Article | published 01 Jul 2025 PLOS ONE https://doi.org/10.1371/journal.pone.0327086

#### **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 05 July 2025] [No new digest content identified]

# PNAS - Proceedings of the National Academy of Sciences of the United States

July 1, 2025 vol. 122 no. 26

https://www.pnas.org/toc/pnas/122/26

Research Article June 25, 2025

# The effects of social media criticism against public health institutions on trust, emotions, and social media engagement

In recent years, trust in US public health and science institutions has faced unprecedented declines, particularly among Republicans/conservatives. To what extent might institutional criticism on social media be responsible for such politically polarized ...

Jonathan Y. Lee

#### **PNAS Nexus**

Volume 4, Issue 5, May 2025 https://academic.oup.com/pnasnexus/issue/4/5 [Reviewed earlier]

# **Prehospital & Disaster Medicine**

Volume 40 - Issue 2 - April 2025 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 194 May 2025 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/194/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/194/suppl/C</a> [Reviewed earlier]

# **Proceedings of the Royal Society B**

July 2025 Volume 292 Issue 2050 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> Table of Contents

# Special feature: The other 1%: Showcasing science and scientists from the Global South and indigenous communities

The other 1%: Showcasing science and scientists from the Global South and indigenous communities. Guest edited by Sarah Brosnan, Stephanie Meirmans, Maurine Neiman, Guadalupe Peralta and Shalene Singh-Shepherd.

#### Research articles

Weak compliance with Nigeria's wildlife trade ban imposed to curb mpox spillovers Charles A. Emogor, et al.

Published: 02 July 2025Article ID:20250471

#### **Public Health**

Volume 244 July 2025 <a href="https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C">https://www.sciencedirect.com/journal/public-health/vol/244/suppl/C</a> [Reviewed earlier]

# **Public Health Ethics**

Volume 18, Issue 1, April 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

#### **Public Health Genomics**

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

#### **Public Health Reports**

Volume 140 Issue 1, January/February 2025 <a href="https://journals.sagepub.com/toc/phrg/140/1">https://journals.sagepub.com/toc/phrg/140/1</a> [Reviewed earlier]

# **Qualitative Health Research**

Volume 35 Issue 7, June 2025 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [Reviewed earlier]

#### **Research Ethics**

Volume 21 Issue 2, April 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

# **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 05 July 2025] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles [No new digest content identified]

#### **Risk Analysis**

Volume 45, Issue 5 Pages: 969-1185 May 2025 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

# **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 05 July 2025]
[No new digest content identified]

# **Royal Society Open Science**

July 2025 Volume 12 Issue 76 <a href="https://royalsocietypublishing.org/toc/rsos/current">https://royalsocietypublishing.org/toc/rsos/current</a> [New issue; No digest content identified]

#### Science

Volume 389| Issue 6755| 3 Jul 2025 https://www.science.org/toc/science/current Editorials

# **Sound policy demands sound science**

BY Michael Kratsios 24 Jun 2025: 7 [Excerpt] ... The federal agencies that are subject to the Gold Standard Science order are only one part of the research ecosystem. Ideally, this effort will set an example for the rest of the research enterprise to do the same, especially the nation's universities, scientific professional societies, and publishers of the scientific literature as they continue their own efforts to improve the quality of research.

The loudest voices in this ongoing conversation may never be convinced, but rather than dismiss Gold Standard Science, the scientific community has the opportunity to take this government-led effort at self-reform and review how it too can support the highest standards of scientific integrity.

# Sluggishness and defensiveness helped enable an executive order on research integrity

BY H. Holden Thorp 24 Jun 2025

[Excerpt]

... A remedy for this situation is for the scientific enterprise to reaffirm its values and hold its members to them, irrespective of actions from a government entity in the United States or elsewhere. Scientific papers should be carefully written not to extend beyond what the evidence supports; adequate amounts of supporting data should be available to researchers who want to repeat analyses and experiments; corrections and retractions to the scientific record should be posted quickly and collaboratively; safeguarding trainees should be prioritized over powerful actors in the system; and sleuths and journalists who turn up problems in research should be recognized as improving science rather than vilified. Although most of the scientific enterprise does live up to these values, the community itself should be the one to hold transgressors accountable without provocation from the federal government. Only then will the message that the vast majority of findings are correct be taken by skeptics as genuine.

It is possible to support science and hold it accountable at the same time. The adherence to a false choice that only one or the other is possible has made it easier for anecdotally driven attacks to succeed politically and for reforms to be externally imposed. It is within the collective control of the scientific enterprise to change the response and the perception.

In Depth

#### Scattershot vaccination fails to slow mpox spread in Congo

BY Jon Cohen 03 Jul 2025: 14-15

Limited vaccine doses weren't used strategically, WHO finds

Policy Forum

# The consequences of letting avian influenza run rampant in US poultry

BY Erin M. Sorrell, et al. 03 Jul 2025: 27-29

The approach proposed by a high-ranking US government official would be dangerous and unethical

# **Science and Engineering Ethics**

Volume 31, Issue 3 June 2025 <a href="https://link.springer.com/journal/11948/volumes-and-issues/31-3">https://link.springer.com/journal/11948/volumes-and-issues/31-3</a> [Reviewed earlier]

#### **Science Translational Medicine**

Volume 17 | Issue 805 | 2 Jul 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

# **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 05 July 2025] [No new digest content identified]

### **Social Science & Medicine**

Volume 380 September 2025 <a href="https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C">https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C</a> [New issue; No digest content identified]

### **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 05 July 2025] [No new digest content identified]

# **Theoretical Medicine and Bioethics**

Volume 46, Issue 3 June 2025 <a href="https://link.springer.com/journal/11017/volumes-and-issues/46-3">https://link.springer.com/journal/11017/volumes-and-issues/46-3</a> [Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 65 May–June 2025 <a href="https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/65/suppl/C">https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/65/suppl/C</a> [Reviewed earlier]

# **Tropical Medicine & International Health**

Volume 30, Issue 6 Pages: i-iv, 459-575 June 2025 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### Vaccine

Volume 60 11 July 2025 <a href="https://www.sciencedirect.com/journal/vaccine/vol/60/suppl/C">https://www.sciencedirect.com/journal/vaccine/vol/60/suppl/C</a> [Reviewed earlier]

#### **Vaccines**

https://www.mdpi.com/journal/vaccines [Accessed 05 July 2025] [No new digest content identified]

# **Value in Health**

July 2025 Volume 28 Issue 7 p979-1140 https://www.valueinhealthjournal.com/current

# ISPOR Report

Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

Eric Barrette, et al.

Published online: April 10, 2025

# **World Development**

Volume 191 July 2025

https://www.sciencedirect.com/journal/world-development/vol/191/suppl/C

[Reviewed earlier]

::::::

# Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

#### **Pre-Print Servers**

#### arxiv

https://arxiv.org/

[Accessed 05 July 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General

Economics]

[No new digest content identified]

#### **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 05 July 2025] [No new digest content identified]

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 05 July 2025]

**Abstract** 

Background There has been significant progress in combating the HIV/AIDS pandemic in the last 15 years. In order to describe towards epidemic control, UNAIDS convened a Global Task Team to recommend targets for 2030 for key HIV interventions. This paper describes the approach to estimate the impact and cost of achieving those targets.

Methods and data We used an HIV simulation model, Goals, to simulate key epidemiological indicators through 2030 is targets are reached in 134 countries with the highest HIV burden. To estimate the cost

of achieving the targets we compiled a unit cost database and applied it to estimate the cost of each intervention in each country for the years 2025 through 2030.

Results Achieving the UNAIDS 2030 targets would reduce the annual number of new HIV infections globally by 77% from 2023 to 2030, from 1.3 million to 300,000. The number of AIDS deaths would decline by 50% over the same period. The number of people living with HIV would decline slightly, from 40 million to 39 million, but would continue declining to 35 million by 2040. The number of people receiving ART would increase from about 31 million to almost 36 million by 2030 before declining to 32 million by 2040. If the targets are achieved the number of new infections would drop below the number of deaths to people living with HIV by 2026. By 2030 there would be 330,000 fewer new infections than deaths

Discussion Achieving the UNAIDS targets for 2030 would reduce the annual number of new HIV infections to just 9% of the peak value in 1995 and AIDS deaths to 13% of the peak value in 2004. In 2030 new infections would be 60% less than deaths to PLHIV, setting us on a path to achieve the end of AIDS as a public health threat.

# <u>Effects Of Good Governance on Health System Performance: An empirical analysis of the WHO Europe region</u>

Levan Samadashvili, Gareth H Rees, Rosemary James, Alison Leary, Thomas Hughes-Waage, Cris Scotter

medRxiv 2025.07.01.25330666; doi: https://doi.org/10.1101/2025.07.01.25330666

# <u>Demographic Factors, Attitudes, and Pre-Existing Conditions Impacting COVID-19 Vaccine</u> <u>Hesitancy</u>

Elizabeth L Kudron, Gabriela R Reguero, Katie M Marker, Jessica Guerra Callaway, Lauren A Vanderlin, Christopher R Gignoux, Colorado Center for Personalized Medicine, Jan T Lowery, Randi K Johnson medRxiv 2025.06.30.25330574; doi: https://doi.org/10.1101/2025.06.30.25330574

# **Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies**

Javad Taleshi, Marina Viñeta Paramo, Allison Watt, Mark Chilvers, Jeffrey ManHay Wong, Jolanta Piszczek, Lea Separovic, Danuta Skowronski, Jia Hu, Pascal M. Lavoie, Hind Sbihi medRxiv 2025.06.27.25330432; doi: https://doi.org/10.1101/2025.06.27.25330432

#### **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

#### **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles [Accessed 05 July 2025] [No new digest content identified]

\* \* \* \*

# **Think Tanks**

**Brookings** [to 05 July 2025] http://www.brookings.edu/ Reports, Events

#### Research

# From aid-driven to investment-driven models of sustainable development

<u>Amar Bhattacharya</u>, <u>Homi Kharas</u>, <u>Charlotte Rivard</u>, and <u>Eleonore Soubeyran</u> June 30, 2025

This paper makes the case for a big push on investments for sustainable development in emerging markets and developing economies (EMDEs).¹ It identifies priority sectors for such investments that have had high-level endorsement at multilateral gatherings over the last few years. It discusses the implications of a big investment push for absorptive capacity at both macroeconomic and microeconomic levels, and for access to finance. It provides an empirical framework based on currently available data that can be improved over time as new information becomes available and priorities get updated. It does not provide an exhaustive list of all the investment priorities that individual countries or development agencies have identified....

# **Center for Global Development** [to 05 July 2025]

https://www.cgd ev.org/ All Research CGD NOTE

#### A New Compact for Health Financing: Donor Priority Setting

Tom Drake et al. June 30, 2025

In 2025, dramatic cuts to global health financing, including the USAID shutdown, have prompted a wave of articles seeking to "reimagine" global development and global health. Our contribution to this literature expands on our existing proposal—the New Compact for health financing between donors and ...

# Box 1. The New Compact for Global Health Financing

The <u>New Compact</u> is a proposed framework to reform global health financing and address persistent challenges in the current aid system, including funding volatility, fragmentation, and limited country ownership. At its core, the New Compact seeks to rebalance the relationship between donor countries and aid recipients by centering three pillars:

- **:: Locally led, evidence-informed priority-setting:** Recipient countries, with technical support as needed, determine their own health priorities based on evidence.
- **:: Domestic-first resource allocation:** Countries commit to financing their highest-priority, essential health services from domestic budgets, reducing reliance on unpredictable external aid for core services.
- **:: Consolidated supplementary aid:** Donor funding is used to expand the package of services beyond what domestic resources can cover, focusing on supplementary and crosscutting needs rather than duplicating or displacing domestic spending.

This approach aims to reduce burdensome fragmentation in external financing, enhance funding security for essential services, and yield greater health impact per dollar spent for both domestic and donor funds. It also empowers national institutions while creating a natural donor exit strategy, as domestic financing expands to crowd out external financing over time.

Chatham House [to 05 July 2025] <a href="https://www.chathamhouse.org/">https://www.chathamhouse.org/</a>
Selected Analysis, Comment, Events No new digest content identified.

**Council on Foreign Relations** [to 05 July 2025]

https://www.cfr.org/media/news-releases

New Releases [Selected]

No new digest content identified.

CSIS [to 05 July 2025] https://www.csis.org/ Reports [Selected] No new digest content identified.

# **Kaiser Family Foundation** [to 05 July 2025]

https://www.kff.org/search/?post\_type=press-release

Newsroom

The Trump Administration's Foreign Aid Review: Status of U.S. Support for Gavi, the

**Vaccine Alliance** 

Published: Jun 30, 2025

# McKinsey Global Institute [to 05 July 2025]

https://www.mckinsey.com/mgi/overview
Latest Research

No new diaest content identified.

# **ODI [Overseas Development Institute]** [to 05 July 2025]

https://odi.org/en/publications/

Publications [Selected]

No new digest content identified.

#### **Pew Research Center** [to 05 July 2025]

https://www.pewresearch.org/ Latest Publications [Selected] short reads Jun 30, 2025

#### Dissatisfaction with democracy remains widespread in many nations

Across 12 high-income countries, a median of 64% of adults say they are dissatisfied with the way their democracy is working, while a median of 35% are satisfied.

**Rand** [to 05 July 2025]

https://www.rand.org/pubs.html Published Research [Selected] Expert Insights Jul 2, 2025

# <u>Data and AI-Enabled Biological Design: Risks Related to Biological Training Data and Opportunities for Governance</u>

The authors of this paper assess the link between biological data and the capabilities of artificial intelligence models trained on large volumes of biological data, then recommend strategies to limit such potentially dangerous capabilities.

Urban Institute [to 05 July 2025]
<a href="https://www.urban.org/publications">https://www.urban.org/publications</a>
New Research Publications - Selected

# **World Economic Forum** [to 05 July 2025]

https://agenda.weforum.org/press/

Media [Selected]

# New Global Platform Launched to Reimagine Regulation in Age of Disruptive Tech

News 04 Jul 2025

- The World Economic Forum and the United Arab Emirates launch the Global Regulatory Innovation Platform to modernize regulation amid rapid technological disruption.
- The initiative will bring together global industry experts to design new adaptive approaches to dynamic sectors such as AI, healthcare and digital finance.
- The platform will pilot solutions and deliver practical tools for governments to develop future-ready regulation fit for a fast-changing world.
- Learn more about the Global Regulatory Innovation Platform here.

•			
:		:	

# Public Consultations/Call for Inputs/Call for Papers

No new digest content identified.

\* \* \* \*

# Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization,

products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.